



HAL
open science

Telomeres: New players in immune-mediated inflammatory diseases?

Anne-Charlotte Heba, Simon Toupance, Djésia Arnone, Laurent Peyrin-Biroulet, Anthanase Benetos, Ndeye Coumba Ndiaye

► To cite this version:

Anne-Charlotte Heba, Simon Toupance, Djésia Arnone, Laurent Peyrin-Biroulet, Anthanase Benetos, et al.. Telomeres: New players in immune-mediated inflammatory diseases?. *Journal of Autoimmunity*, 2021, 123, pp.102699. 10.1016/j.jaut.2021.102699 . hal-03311745

HAL Id: hal-03311745

<https://hal.univ-lorraine.fr/hal-03311745>

Submitted on 2 Aug 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Telomeres: New Players In Immune-Mediated Inflammatory Diseases?

1 **Anne-Charlotte Heba^a, Simon Toupance^b, Djésia Arnone^a, Laurent Peyrin-Biroulet^{a,c},**
2 **Anthanase Benetos^{b,d}, Ndeye Coumba Ndiaye^{a*}**

3 ^aNGERE (Nutrition-Genetics and Exposure to Environmental Risks), INSERM, University of
4 Lorraine, F-54000, Nancy, France.

5 ^bDCAC (Acute and Chronic Cardiovascular Failure), INSERM, University of Lorraine, F-54000,
6 Nancy, France.

7 ^cDepartment of Gastroenterology, Nancy University Hospital, University of Lorraine, F-54000,
8 Nancy, France.

9 ^dAging Diseases Gerontology and Palliative Care unit, Nancy University Hospital, University of
10 Lorraine, F-54000, Nancy, France.

11 * Correspondence:

12 Ndeye Coumba Ndiaye

13 University of Lorraine UMRS1256 NGERE (Nutrition-Genetics and Exposure to Environmental
14 Risks)

15 9 Avenue de la Forêt de Haye, 54500 Vandœuvre-lès-Nancy France

16 ndeye-coumba.ndiaye@univ-lorraine.fr

17

18 Abstract

19 Telomeres are repetitive DNA sequences located at the ends of linear chromosomes that preserve the
20 integrity and stability of the genome. Telomere dysfunctions due to short telomeres or altered
21 telomere structures can ultimately lead to replicative cellular senescence and chromosomal
22 instability, both mechanisms being hallmarks of ageing. Chronic inflammation, oxidative stress and
23 finally telomere length (TL) dynamics have been shown to be involved in various age-related non-
24 communicable diseases (NCDs). Immune-mediated inflammatory diseases (IMIDs), including
25 affections such as inflammatory bowel disease, psoriasis, rheumatoid arthritis, spondyloarthritis and
26 uveitis belong to this group of age-related NCDs. Although in recent years, we have witnessed the
27 emergence of studies in the literature linking these IMIDs to TL dynamics, the causality between
28 these diseases and telomere attrition is still unclear and controversial. In this review, we provide an
29 overview of available studies on telomere dynamics and discuss the utility of TL measurements in
30 immune-mediated inflammatory diseases.

31 **Keywords: Telomere, Dynamics, Immune-Mediated Inflammatory Diseases**

32

33 **1 Introduction**

34 Telomeres are complex heterochromatin structures at the natural ends of linear chromosomes
35 dedicated to the preservation and stability of the genome [1,2]. Telomere length (TL) has been
36 associated to the pace of ageing and to the onset/severity of ageing-related diseases [3].

37 At the time of birth, TL is highly variable in mammals, specifically humans [3–5], and appears to be
38 associated with parental TL [6–19], gender [16,17,20–29] and ethnicity [25,26,29–32]. From this
39 starting point, telomere attrition accompanies normal ageing. It is rapid during the first 20 years of
40 life, then substantially slowed down [33–35] until telomeres reach a critical length and a DNA
41 damage response is initiated, committing the cell to senescence or apoptosis [36–38]. The secretome
42 associated with telomere-induced cell senescence impacts surrounding cells and can limit the
43 regenerative capacity of affected tissues by compromising the function of tissue-specific stem and
44 progenitor cells [39–41]. Thereby, the accumulation of senescent cells, in addition to inflammation,
45 leads to a loss of tissue function and ultimately to organismal ageing [42].

46 Telomeres shortening rate can be accelerated by inflammation and oxidative stress *in vitro* and these
47 phenomena participate in the ageing process [43]. Moreover, chronic inflammation, oxidative stress
48 and lastly TL dynamics have been shown to be involved in various ageing-related non-communicable
49 diseases (NCDs) such as cardiovascular diseases [44–47], cancer [48–50] and immune-associated
50 diseases [51].

51 Immune-mediated inflammatory diseases (IMIDs) also belong to this group of NCDs which are the
52 leading causes of morbidity and mortality worldwide and represent a burden on national economies
53 whether in low, middle- or high-income countries [52,53].

54 IMID is a concept used to collectively describe a group of *prima facie* unrelated disorders that share
55 common inflammatory pathways [54]. They include conditions such as inflammatory bowel disease
56 (IBD), psoriasis (PS), rheumatoid arthritis (RA), spondyloarthritis, and uveitis [51,55] and are
57 characterized by an immune dysregulation that may afflict any organ system and result in significant
58 morbidity, reduced quality of life and premature death [56]. Although the aetiology of these
59 conditions is unknown, advances in molecular research have revealed that an imbalance in
60 inflammatory cytokines which accelerated cellular ageing is central to their pathogenesis [56]. In past
61 years, we have seen the emergence in the literature of studies relating these pathologies to TL
62 dynamics [57–73] but nowhere near to the scientific production dedicated to other NCDs.

63 In this review we briefly cover mechanisms involved in TL dynamics and then focus on the results of
64 telomeres studies on IMIDs available and their methodological implications.

65 **2 Telomere/telomerase biology**

66 The natural ends of linear chromosomes require unique genetic and structural adaptations to facilitate
67 the protection of genetic material [1]. This is made possible by the sequestration of the telomeric
68 sequence into a protective nucleoprotein cap that masks the double strand ends from constitutive
69 exposure to the DNA damage response machinery [2]. The relationship between capping
70 requirements with telomere replication and the enzymatic processing steps obligatory for telomere
71 function is complex [2]. Telomeric proteins and their interacting factors create an environment at
72 chromosome ends that inhibits DNA repair there, however, the repair machinery is essential for
73 proper telomere function [74].

74 2.1 Biology

75 Telomeres are composed of hundreds to thousands of tandem DNA repeat sequences associated with
76 specific proteins. In humans, the hexameric sequence of the repeat is TTAGGG in one strand and
77 CCCTAA in the other [2,75]. The 3' end of telomere terminates with a single-stranded overhang,
78 which folds back and invades the double-stranded telomeric helix, forming a specific structure called
79 T loop [76]. Six protective proteins associated with telomere DNA (TRF1, TRF2, TIN2, POT1,
80 TPP1, and RAP1), collectively termed shelterin complex, stabilize the T-Loop and prevent telomeres
81 from inadvertently activating DNA damage signalling and double-strand break repair pathways [75].
82 Shelterin must prevent hyper-resection under most conditions. Sfeir et de Lange speculate that the
83 mechanism by which shelterin fulfils this task is related to how it governs the formation of the
84 correct telomeric overhangs after DNA replication [77] (fig. 1.A).

85 However, each normal cell division results in the loss of small parts of chromosomes' far-end
86 sequences because of the phenomenon known as the end replication problem [78–81], causing
87 telomere length shortening. Once a telomere reaches a critical length, the cell enters a state of
88 permanent cell cycle arrest *i.e.*, intrinsic replicative senescence potentially leading to its programmed
89 death *i.e.*, apoptosis. Exposure to external factors, such as oxidative stress or ultraviolet light can
90 induce premature stress-related senescence. Senescent cells display senescence-associated secretory
91 phenotype (SASP) as long as they remain metabolically active [82] and their accumulation in tissues
92 and resulting SASP-induced proinflammatory state combined with a progressively dysfunctional
93 immune system – dubbed inflammaging – ends up impacting the whole organism.

94 Maintenance of the integrity of telomeres requires telomerase – a specific RNA-dependent DNA
95 polymerase enzyme complex that carries its own integral RNA template (TERC) and adds telomeric
96 repeats to the ends of chromosomes using a telomerase reverse transcriptase (TERT) [83–86]. TERT
97 sub-unit uses TERC as a template to extend the 3' end of the chromosome [83–85] (fig. 1.A). This
98 enzyme responsible for generating *de novo* telomere sequences is active during gestation and in
99 immature undifferentiated cells but predominantly inactive in human somatic cells (except in
100 lymphocytes) [83]. Its activation is a key component of rapid cell division in many cancer cells and
101 occurs in 85-90% of all human cancers [87,88] although it is not a dominantly acting oncogene that
102 can induce physiological transformation by itself [89].

103 The progressive attrition of telomeres, which is believed to be an initial proliferative barrier to
104 tumour formation in humans and other long-lived animals [90–92], is directly involved in ageing
105 whether it is a natural or pathological process [36,37] and accelerated ageing-associated diseases are
106 characterized by increased cellular senescence.

107 The clocking mechanism of telomere/telomerase biology can thus be put in parallel with the
108 countdown initiated by chronic inflammatory disorders. Indeed, telomere/telomerase biology
109 impairment has been previously connected to chronic inflammation and to the subsequent immune
110 system disruption of affected patients [43,93]

111 2.2 Telomeres and lifestyle

112 As mentioned previously, telomere attrition during the highly proliferative early years of life – during
113 intrauterine life even – is rapid [8,9,33–35,94–100]. Benetos et al. reported an average TL attrition of
114 40.7 base pairs (bp) per year in leukocytes of children under 14 from the STANISLAS Study, twice
115 the attrition rate of their parents [35]. Children can thus be greatly impacted by external factors
116 altering cellular replication pacing, especially in utero. Maternal exposures during pregnancy for

117 instance can reflect on fetal TL [13,99,101–109] and maternal nutrition [110,111], weight
118 [99,101,112], mental health [102–104,107] and smoking [103,105,106,108] can exert a
119 ‘programming’ effect on their offspring’s TL.

120 During adulthood on the contrary, telomere attrition is relatively low [33–35] – between 23.6 and
121 31.2 bp per year in leukocytes – and has little effect on TL ranking in population [33]. Lifestyle is
122 thus unlikely to exert a major impact on TL. However, the effect of many lifestyle factors which are
123 involved in IMIDs pathophysiology on telomere dynamics have been reported in the literature, but
124 the study designs rarely make it possible to decide on causality.

125 For instance, studies about the effect of smoking on TL are contradictory even if it seems logical at
126 first that the oxidative stress resulting from this behaviour could cause accelerated telomere attrition
127 and faster ageing [113–116]. It is important to note that many cross-sectional studies found
128 association between short TL and smoking habits [113–115,117–122] while longitudinal studies
129 never found any association between smoking and increased telomere attrition [114,123–129]. This
130 observation also applies to findings on the cross-sectional associations between short telomeres and
131 diet [130–136], physical activity [135–148] and body mass index [117,129,130,136,149–151] which
132 are not corroborated in longitudinal studies [135,152–154]. Recently, it was suggested that short
133 telomeres could influence behaviour and that it is in fact this characteristic that could lead to
134 disadvantageous behaviours such as smoking [125]. One explanation may be that children tend to
135 replicate their parents’ lifestyle, diet, and physical activity well into adulthood [155–161]. Similarly
136 they often share socio-economic status [157,160,162–167]. As a result, people with shorter telomeres
137 are more likely to develop metabolic disorders [168–178] or fall into categories of populations
138 presenting disadvantageous behaviours [113–126,130–136].

139 **3 IMIDS and telomere**

140 **3.1 Inflammatory bowel diseases**

141 **Inflammatory bowel diseases**, mainly Crohn's disease (CD) and ulcerative colitis (UC), have
142 emerged as a major public health concern of industrialized countries in the past years [179,180]. IBD
143 imposes health and economic burdens on communities worldwide, and substantially reduces patients’
144 quality of life [181]. It can affect people of all ages, including children and geriatric populations, and
145 can impact all aspects of life [180]. It is estimated that more than 3 million people in the USA and
146 Europe have IBD [181].

147 CD is a chronic inflammatory disease potentially affecting the entire gastrointestinal tract while UC
148 is a chronic, recurrent inflammation localized in the colon. UC patients can be characterized as
149 progressors when they present a dysplasia elsewhere in the colon, usually with genomic instability
150 and mitochondrial dysfunction. The term non progressors is used for dysplasia-free patients [182–
151 184].

152 In 2020, the study of 3 IBD families with 11 affected members over three successive generations
153 concluded that short telomeres, measured in leukocytes, was unlikely to be involved in mechanisms
154 of possible genetic anticipation of the disease [57]. Indeed, TL was not associated with earlier age at
155 onset or severity of IBD in members of successive generations affected by the disease [57]. However,
156 it was demonstrated that TL was shorter in the colonic mucosa of UC subjects compared to age-
157 matched controls [185,186] and associated with more severe clinical phenotypes of UC [185]. A
158 study of TL in colonocytes and leukocytes from UC patients showed shorter telomeres in both cell
159 types in UC patients than in matched controls [58]. Interestingly, the difference in TL in colonocytes

160 was more pronounced in early-onset UC patients (aged less than 39 years) [58]. The short TL in
161 colonocytes could explain the increased and early cancer risk in this disease. An increase in γ H2AX
162 foci, which are early cellular response to DNA double-strand breaks through rapid phosphorylation at
163 Ser-139 of H2AX – the minor variant of histone H2A –, was also found in colonocytes and may
164 reflect oxidative damage secondary to inflammation [58]. In a study with 14 UC patients, an
165 increased load of ultra-short telomeres, as well as a shorter mean TL, were found associated with
166 dysplasia in longstanding UC. Furthermore, the load of ultra-short telomeres was also increased in
167 progressors compared to non-progressors [187]. Another study of 9 UC patients with high-grade
168 dysplasia compared to 4 UC patients without dysplasia supports a model in which inflammation,
169 short telomeres and senescence are the background to tumour progression in progressive UC [59].
170 Senescence acts as a tumour suppressor mechanism, preventing colons from progressing beyond low-
171 grade dysplasia [59]. However, it has been demonstrated that in colonic mucosa, short telomeres are
172 correlated with chromosomal instability [184]. Eventually some colonocytes bypass senescence and
173 transform, coinciding with the lengthening of telomeres through activation of telomerase and the loss
174 of p53 tumor suppression function [59]. This allows colonocytes with genetic damage to proliferate
175 and progress to high-grade dysplasia and cancer [59]. In contrast to these results, another study with
176 18 controls, 19 UC and 17 CD concluded that there was no difference in telomere length in
177 peripheral blood mononuclear cells (PBMCs) between these three groups [60]. (Table 1; Fig. 1.B).

178 Another study, with 18 UC, 13 CD patients and 13 controls, observed the downregulation of TRF2
179 and RAPI mRNA expression in CD25+ T-lymphocytes in IBD. This could lead to the destabilisation
180 of the T-loop structure in these cells and may contribute to the telomeric fusions and chromosomal
181 abnormalities observed in UC [61]. These findings may also indicate a systemic process of telomere
182 uncapping that could represent a putative biomarker for IBD associated colon cancer risk [61]. (Table
183 1; Fig. 1.B).

184 Overall, these studies concur on the presence of short telomeres in colon mucosa of IBD patients.
185 Short TL and telomere dysfunction are also found in leukocytes from these patients. Short telomeres
186 could be the result of higher telomere attrition due to chronic inflammation and higher cell turn-over
187 or partially due to the effect of lifestyle factors such as diet and smoking [113,123,135,188] that are
188 also involved in the aetiology of IBD [189]. However, shorter telomeres could precede IBD and play
189 a role in the pathogenesis. Indeed, in a study on 33 patients with UC, 14 progressors and 19 non-
190 progressors, shorter telomeres were found associated with clonal expansions in nondysplastic
191 biopsies from UC progressors with early-onset of disease (younger than 50 years of age) [62]. Short
192 TL in leukocyte has already been associated with clonal expansion, known as clonal haematopoiesis
193 of indeterminate potential (CHIP) [190,191]. Short telomeres and telomere dysfunction may also play
194 a role in initiating inflammation. Short LTL has been recently linked to the upregulation of NLRP3
195 inflammasome [192,193], a system that may contribute to IBD susceptibility [194–196]. Moreover, a
196 recent study showed that telomere dysfunction-induced activation of the ATM-YAP1-pro-IL-18
197 pathway in intestinal epithelium is a primary initiator and driver of colon inflammation [197]. (Table
198 1; Fig. 1.B).

199 **3.2 Psoriasis**

200 **Psoriasis** is a chronic inflammatory disease of uncertain aetiology characterised by scaly
201 erythematous plaques that can lead to significant physical and psychological distress, affecting
202 approximately 125 million people worldwide [198–200].

203 Wu et al demonstrated for the first time that increased telomerase activity can be detected in freshly
204 obtained non-stimulated PBMCs from patients with atopic dermatitis (AD), indicating the
205 lymphocytes have already been activated *in vivo* or that a subpopulation of 'immature' lymphocytes
206 may be present [65]. The relative reduced telomerase activity of PBMCs to multiple stimulators in
207 patients with AD seemed to be associated with their excessive stimulation *in vivo* and their decreased
208 functional capacity *in vitro* [65]. The authors have published a second study showcasing similar
209 results in T lymphocytes from blood of patients with AD and psoriasis: increased telomerase activity
210 was found together with reduced TL as compared to healthy controls, also indicating an *in vivo*
211 activation of T lymphocytes [64] (table 1; Fig. 1.B). A third study focusing on patients with psoriasis
212 confirmed the higher telomerase activity in PBMCs from patients [63]. In addition, telomerase
213 activity of PBMC in psoriatic patients correlated positively with disease severity [63].

214 These three studies observe short telomeres and an increase in telomerase activity in circulating cells
215 from patients with psoriasis. Short telomeres may reflect increased TL attrition due to cell
216 proliferation, which would support the view that the affected T cells have gone through a large
217 number of cell divisions because of chronic stimulation *in vivo* [64] (Table 1; Fig. 1.B)

218 3.3 Spondyloarthritis

219 **Spondyloarthritis** is a group of inflammatory disorders affecting the spine (spondylitis) and joints
220 (arthritis) including ankylosing spondylitis, axial spondyloarthritis, enteropathic spondyloarthritis or
221 IBD-associated spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis and reactive arthritis
222 which is a subgroup of juvenile idiopathic arthritis [201]. These rheumatic diseases have common
223 features, which may be clinical - inflammation of the axial skeleton (sacroiliac joint and spine) or
224 possibly of the peripheral skeleton - and genetic - association with the *HLA-B27* gene [202–204].

225 Ankylosing spondylitis, the most common spondyloarthritis, is a chronic inflammatory disease of the
226 axial spine that can manifest with various clinical signs and symptoms [205]. Chronic back pain and
227 progressive spinal stiffness are the most common features of the disease [205]. Involvement of the
228 spine and sacroiliac joints, peripheral joints, digits, entheses are characteristic of the disease [205].
229 Impaired spinal mobility, postural abnormalities, buttock pain, hip pain, peripheral arthritis,
230 enthesitis, and dactylitis are all associated with ankylosing spondylitis [205]. This chronic
231 inflammatory rheumatic disease has an estimated prevalence per 10,000 to 23.8 in Europe, 16.7 in
232 Asia, 31.9 in North America, 10.2 in Latin America and 7.4 in Africa [206].

233 In 2010, Tamayo et al. observed in a cross-sectional study that patients with several rheumatic
234 disorders – notably rheumatoid arthritis (n=86) which will be outlined in the following paragraph,
235 psoriatic arthritis (n=56) and ankylosing spondylitis (n=59) – showed longer telomeres in PBMCs
236 when compared with 130 controls [207]. Four years later, the same team continued its investigations
237 on spondyloarthritis and reported that the presence of chronic inflammatory components in psoriatic
238 arthritis could be associated with a higher telomere size in peripheral blood leukocytes (PBL), unlike
239 in cutaneous psoriasis [66]. According to the authors, the rate of telomere loss in PBL was higher in
240 psoriatic arthritis patients (n=42) than in ankylosing spondylitis patients (n=44), revealing a
241 difference in telomere physiology from PBL between both spondylarthritis. [66]. However, reported
242 TL attrition was extremely high in comparison to what could be expected in adults [35] and these
243 results should thus be considered with caution.

244 Regarding axial spondylarthritis (aSpA) – a group that includes ankylosing spondylitis (radiographic
245 axial spondylarthritis) [204,208] –shorter telomeres were found in CD4+ and CD8+ T cell subsets in

246 young patients (under 35 years), as well as impaired telomerase in aSpA patients with rheumatoid
247 arthritis [209] (Table 1; Fig. 1.B).

248 **3.4 Rheumatoid arthritis**

249 **Rheumatoid arthritis** is a systemic inflammatory condition that primarily affects the synovial
250 membrane of affected joints [210]. Extra-articular manifestations are common and may involve any
251 organ system. Rheumatoid arthritis (RA) affects approximately 1% of the adult population and is
252 associated with chronic pain, disability and increased mortality [56].

253 Telomere length has been studied in the context of RA and first results were contradictory, some
254 studies finding shorter TL in leukocytes from patients than in those from healthy controls [67,211]
255 and other finding rather longer TL in patients [207]. Recently, two meta-analyses confirmed the
256 presence of short TL in patients suffering from RA[212,213]. Formerly, this was suspected to be a
257 consequence of chronic inflammatory activity on TL attrition. However, a Mendelian randomization
258 analysis found that genetically predicted longer TL was associated with a reduced risk of RA [213]
259 excluding reverse causality. This is in concordance with the finding that TL in RA patients do not
260 correlate with disease duration as it should if the disease was driving the association [67].
261 Interestingly, RA patients present short TL in hematopoietic progenitor cells (HPC) [68]. Short
262 telomere-related defective HPC proliferative function may be a potential pathogenic factor in RA.
263 Telomerase expression and activity have also been observed in RA and are deregulated [70,214]
264 (Table 1; Fig. 1.B).

265 **3.5 Uveitis**

266 **Uveitis** is a term used to describe inflammatory processes of the portion of the eye known as the
267 uvea, which is composed of the iris, ciliary body, and the choroid. Symptoms and consequences can
268 range from pain and conjunctival injection to complete vision loss [215]. Uveitis occurs with an
269 incidence of approximately 20 individuals per 100,000 per year, resulting in overall population-based
270 prevalence estimates ranging from approximately 40 to 400 individuals per 100,000 [216].

271 One study involving 91 Birdshot Uveitis patients and 150 unrelated healthy controls showed longer
272 telomeres compared to healthy controls which implies sophisticated telomere biology in chronic
273 inflammation [73]. (table 1; Fig. 1.B). This study alone does not allow to conclude on the impact of
274 telomeres in uveitis.

275 As it is the case in most NCDs, telomere dynamics is unquestionably involved in IMIDs whether it
276 be through the deleterious lifestyle leading to their onset, through increased telomere attrition in
277 response high cellular turnover due to chronic inflammation or through a determinant role in the
278 disease onset and progression. Mechanistics in play remain to be elucidated, as for pathologies
279 sharing common inflammatory pathways [54], contradictory phenomena are observed: short
280 telomeres and increased telomerase activity in IBD, psoriasis and RA, and potentially longer
281 telomeres in spondyloarthritis and uveitis that must be further investigated.

282 **4 Perspectives**

283 Unlike studies focused on telomere dynamics and other NCDs, those focused on IMIDs tend to
284 gather relatively narrow populations with great difficulty to find healthy controls. This is partly due
285 to the nature of the biological material required for comparison which is difficult to obtain in healthy
286 subjects and questions the statistical power of the majority of results. In addition, most of these

287 studies used a telomere length measurement methodology based on qPCR that is not the most
288 suitable method for such narrow populations [217,218].

289 Many studies support the hypothesis that the rate of telomere attrition in adulthood can be
290 substantially affected by different exposures to environmental factors and / or diseases. However, the
291 majority of these studies report a cross-sectional association, without being able to exclude potential
292 confounders, which does not necessarily prove a causal association between exposures and
293 subsequent telomere attrition [219,220]. This causal association could be established in longitudinal
294 studies, where so for the moment, the results differ from cross-sectional studies. Furthermore, the
295 discrepancies in sizes and characteristics of study populations (gender, age, racial / ethnic
296 background), as well as the different measurements (blood, saliva, ...) and analysis methods (qPCR,
297 Q-FISH, statistical adjustments...) of TL may partly contribute to the inconsistency of the results.
298 This also applies to the recurrent conflation of telomere length and telomere shortening in the
299 literature [220–223].

300 Drawing conclusions about telomere shortening without substantial prospective data is challenging
301 and must be further supported with appropriate methodologies. Table 1 illustrates this gap between
302 proper methodologies and adequate conclusions as cross-sectional studies often lead authors to a
303 conclusion on impaired attrition (highlighted in red in table 1).

304 Furthermore, telomere length measured only during adulthood provides merely partial information
305 about telomere dynamics. Repeated measurements covering the entire lifespan of individuals,
306 considering additionally genetic factors and early childhood exposures could provide better insight
307 on adulthood telomere dynamics even though such longitudinal data would be extremely difficult to
308 gather [114].

309 A better understanding of suitable telomeres analyses, resulting in a better understanding of
310 telomeres dynamics, may allow their therapeutic use [224]. Anti-aging or regenerative applications
311 require telomeres up-regulation, which is often associated with telomere attrition [225]. In contrast,
312 anti-cancer applications require suppression of various genes integral to telomere maintenance such
313 as telomerase, telomerase RNA components and the shelterin complex, thereby counteracting the
314 immortality process of cancer cells [50,226–229].

315 Several questions remain unanswered: is the telomere length at birth highly predictive of IMIDs
316 onset? Why is telomere attrition, which seems to be a common trait in IMIDs, efficiently
317 compensated by telomerase activation in some of these disorders while insufficient in others? And in
318 the same way, what mechanism makes it possible to observe a difference between patients with the
319 same pathology? Of course, the specificity of tissues impacted is to consider, but is that the only
320 difference? Can telomere modulation represent a new therapeutic approach in IMIDs?

321

322

323 **5 Conflict of Interest**

324 *Prof. Peyrin-Biroulet reports personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots,*
325 *Pharmacosmos, Celltrion, Takeda, Boehringer Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz,*
326 *Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena,*
327 *Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma,*

328 *Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera,*
329 *Theravance; grants from Abbvie, MSD, Takeda; stock options : CTMA.*

330 *The remaining authors declare that the research was conducted in the absence of any commercial or*
331 *financial relationship that could be construed as a potential conflict of interest.*

332 **6 Author Contributions**

333 All authors listed have made a substantial, direct and intellectual contribution to the work, and
334 approved it for publication.

335 **7 Funding**

336 Doctoral Fellowship from "Reseau Lorrain des Maladies inflammatoires chroniques intestinales"
337 MICILOR and Association des chefs de service from CHRU de Nancy to ACH. Research award
338 2020 from "Societe Francophone de Nutrition Clinique et Métabolisme" SFNCM
339 [GRANT_NUMBER: SFNCM2020] to DA.

340 **8 References**

- 341 [1] A.M. Wood, K. Laster, E.L. Rice, S.T. Kosak, A beginning of the end: new insights into the
342 functional organization of telomeres, *Nucleus*. 6 (2015) 172–178.
343 <https://doi.org/10.1080/19491034.2015.1048407>.
- 344 [2] C.W. Greider, Telomeres, *Curr Opin Cell Biol*. 3 (1991) 444–451.
345 [https://doi.org/10.1016/0955-0674\(91\)90072-7](https://doi.org/10.1016/0955-0674(91)90072-7).
- 346 [3] K.J. Turner, V. Vasu, D.K. Griffin, Telomere Biology and Human Phenotype, *Cells*. 8 (2019).
347 <https://doi.org/10.3390/cells8010073>.
- 348 [4] V. Vasu, K.J. Turner, S. George, J. Greenall, P. Slijepcevic, D.K. Griffin, Preterm infants have
349 significantly longer telomeres than their term born counterparts, *PLoS One*. 12 (2017).
350 <https://doi.org/10.1371/journal.pone.0180082>.
- 351 [5] F. de Zegher, M. Díaz, A. Lopez-Bermejo, L. Ibáñez, Recognition of a sequence: more growth
352 before birth, longer telomeres at birth, more lean mass after birth, *Pediatr Obes*. 12 (2017)
353 274–279. <https://doi.org/10.1111/ijpo.12137>.
- 354 [6] K. Nordfjäll, A. Larefalk, P. Lindgren, D. Holmberg, G. Roos, Telomere length and heredity:
355 Indications of paternal inheritance, *Proc Natl Acad Sci U S A*. 102 (2005) 16374–16378.
356 <https://doi.org/10.1073/pnas.0501724102>.
- 357 [7] O.T. Njajou, R.M. Cawthon, C.M. Damcott, S.-H. Wu, S. Ott, M.J. Garant, E.H. Blackburn,
358 B.D. Mitchell, A.R. Shuldiner, W.-C. Hsueh, Telomere length is paternally inherited and is
359 associated with parental lifespan, *Proc Natl Acad Sci U S A*. 104 (2007) 12135–12139.
360 <https://doi.org/10.1073/pnas.0702703104>.
- 361 [8] P. Factor-Litvak, E. Susser, K. Kezios, I. McKeague, J.D. Kark, M. Hoffman, M. Kimura, R.
362 Wapner, A. Aviv, Leukocyte Telomere Length in Newborns: Implications for the Role of
363 Telomeres in Human Disease, *Pediatrics*. 137 (2016). <https://doi.org/10.1542/peds.2015-3927>.
- 364 [9] A. Akkad, R. Hastings, J.C. Konje, S.C. Bell, H. Thurston, B. Williams, Telomere length in
365 small-for-gestational-age babies, *BJOG*. 113 (2006) 318–323. <https://doi.org/10.1111/j.1471-0528.2005.00839.x>.

- 367 [10] K.M. Ross, J.E. Carroll, S. Horvath, C.J. Hobel, M.E. Coussons-Read, C. Dunkel Schetter,
368 Epigenetic age and pregnancy outcomes: GrimAge acceleration is associated with shorter
369 gestational length and lower birthweight, *Clin Epigenetics*. 12 (2020) 120.
370 <https://doi.org/10.1186/s13148-020-00909-2>.
- 371 [11] M. Kimura, L.F. Cherkas, B.S. Kato, S. Demissie, J.B. Hjelmborg, M. Brimacombe, A.
372 Cupples, J.L. Hunkin, J.P. Gardner, X. Lu, X. Cao, M. Sastrasin, M.A. Province, S.C. Hunt,
373 K. Christensen, D. Levy, T.D. Spector, A. Aviv, Offspring's leukocyte telomere length,
374 paternal age, and telomere elongation in sperm, *PLoS Genet*. 4 (2008) e37.
375 <https://doi.org/10.1371/journal.pgen.0040037>.
- 376 [12] A. Aviv, E. Susser, Leukocyte telomere length and the father's age enigma: implications for
377 population health and for life course, *Int J Epidemiol*. 42 (2013) 457–462.
378 <https://doi.org/10.1093/ije/dys236>.
- 379 [13] L. Broer, V. Codd, D.R. Nyholt, J. Deelen, M. Mangino, G. Willemsen, E. Albrecht, N. Amin,
380 M. Beekman, E.J.C. de Geus, A. Henders, C.P. Nelson, C.J. Steves, M.J. Wright, A.J.M. de
381 Craen, A. Isaacs, M. Matthews, A. Moayyeri, G.W. Montgomery, B.A. Oostra, J.M. Vink,
382 T.D. Spector, P.E. Slagboom, N.G. Martin, N.J. Samani, C.M. van Duijn, D.I. Boomsma,
383 Meta-analysis of telomere length in 19,713 subjects reveals high heritability, stronger maternal
384 inheritance and a paternal age effect, *Eur J Hum Genet*. 21 (2013) 1163–1168.
385 <https://doi.org/10.1038/ejhg.2012.303>.
- 386 [14] J.B. Hjelmborg, C. Dalgård, M. Mangino, T.D. Spector, U. Halekoh, S. Möller, M. Kimura, K.
387 Horvath, J.D. Kark, K. Christensen, K.O. Kyvik, A. Aviv, Paternal age and telomere length in
388 twins: the germ stem cell selection paradigm, *Aging Cell*. 14 (2015) 701–703.
389 <https://doi.org/10.1111/accel.12334>.
- 390 [15] N.M. Marchetto, R.A. Glynn, M.L. Ferry, M. Ostojic, S.M. Wolff, R. Yao, M.F. Haussmann,
391 Prenatal stress and newborn telomere length, *Am J Obstet Gynecol*. 215 (2016) 94.e1–8.
392 <https://doi.org/10.1016/j.ajog.2016.01.177>.
- 393 [16] M. Bosquet Enlow, V. Bollati, G. Sideridis, J.D. Flom, M. Hoxha, M.R. Hacker, R.J. Wright,
394 Sex differences in effects of maternal risk and protective factors in childhood and pregnancy
395 on newborn telomere length, *Psychoneuroendocrinology*. 95 (2018) 74–85.
396 <https://doi.org/10.1016/j.psyneuen.2018.05.025>.
- 397 [17] M. Bosquet Enlow, G. Sideridis, V. Bollati, M. Hoxha, M.R. Hacker, R.J. Wright, Maternal
398 cortisol output in pregnancy and newborn telomere length: Evidence for sex-specific effects,
399 *Psychoneuroendocrinology*. 102 (2019) 225–235.
400 <https://doi.org/10.1016/j.psyneuen.2018.12.222>.
- 401 [18] D.A. Delgado, C. Zhang, K. Gleason, K. Demanelis, L.S. Chen, J. Gao, S. Roy, J. Shinkle, M.
402 Sabarinathan, M. Argos, L. Tong, A. Ahmed, T. Islam, M. Rakibuz-Zaman, G. Sarwar, H.
403 Shahriar, M. Rahman, M. Yunus, J.A. Doherty, F. Jasmine, M.G. Kibriya, H. Ahsan, B.L.
404 Pierce, The contribution of parent-to-offspring transmission of telomeres to the heritability of
405 telomere length in humans, *Hum Genet*. 138 (2019) 49–60. <https://doi.org/10.1007/s00439-018-1964-2>.
- 407 [19] M. Lulkiewicz, J. Bajsert, P. Kopczynski, W. Barczak, B. Rubis, Telomere length: how the
408 length makes a difference, *Mol Biol Rep*. 47 (2020) 7181–7188.
409 <https://doi.org/10.1007/s11033-020-05551-y>.

- 410 [20] A. Benetos, K. Okuda, M. Lajemi, M. Kimura, F. Thomas, J. Skurnick, C. Labat, K. Bean, A.
411 Aviv, Telomere length as an indicator of biological aging: the gender effect and relation with
412 pulse pressure and pulse wave velocity, *Hypertension*. 37 (2001) 381–385.
413 <https://doi.org/10.1161/01.hyp.37.2.381>.
- 414 [21] T.S. Nawrot, J.A. Staessen, J.P. Gardner, A. Aviv, Telomere length and possible link to X
415 chromosome, *Lancet*. 363 (2004) 507–510. [https://doi.org/10.1016/S0140-6736\(04\)15535-9](https://doi.org/10.1016/S0140-6736(04)15535-9).
- 416 [22] S. Bekaert, T. De Meyer, E.R. Rietzschel, M.L. De Buyzere, D. De Bacquer, M. Langlois, P.
417 Segers, L. Cooman, P. Van Damme, P. Cassiman, W. Van Criekinge, P. Verdonck, G.G. De
418 Backer, T.C. Gillebert, P. Van Oostveldt, Asklepios investigators, Telomere length and
419 cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease,
420 *Aging Cell*. 6 (2007) 639–647. <https://doi.org/10.1111/j.1474-9726.2007.00321.x>.
- 421 [23] M. Gardner, D. Bann, L. Wiley, R. Cooper, R. Hardy, D. Nitsch, C. Martin-Ruiz, P. Shiels,
422 A.A. Sayer, M. Barbieri, S. Bekaert, C. Bischoff, A. Brooks-Wilson, W. Chen, C. Cooper, K.
423 Christensen, T. De Meyer, I. Deary, G. Der, A. Diez Roux, A. Fitzpatrick, A. Hajat, J.
424 Halaschek-Wiener, S. Harris, S.C. Hunt, C. Jagger, H.-S. Jeon, R. Kaplan, M. Kimura, P.
425 Lansdorp, C. Li, T. Maeda, M. Mangino, T.S. Nawrot, P. Nilsson, K. Nordfjall, G. Paolisso, F.
426 Ren, K. Riabowol, T. Robertson, G. Roos, J.A. Staessen, T. Spector, N. Tang, B. Unryn, P.
427 van der Harst, J. Woo, C. Xing, M.E. Yadegarfar, J.Y. Park, N. Young, D. Kuh, T. von
428 Zglinicki, Y. Ben-Shlomo, Halcyon study team, Gender and telomere length: systematic
429 review and meta-analysis, *Exp Gerontol*. 51 (2014) 15–27.
430 <https://doi.org/10.1016/j.exger.2013.12.004>.
- 431 [24] O.M. Wolkowitz, D.V. Jeste, A.S. Martin, J. Lin, R.E. Daly, C. Reuter, H. Kraemer,
432 Leukocyte telomere length: Effects of schizophrenia, age, and gender, *J Psychiatr Res*. 85
433 (2017) 42–48. <https://doi.org/10.1016/j.jpsychires.2016.10.015>.
- 434 [25] L. Brown, B. Needham, J. Ailshire, Telomere Length Among Older U.S. Adults: Differences
435 by Race/Ethnicity, Gender, and Age, *J Aging Health*. 29 (2017) 1350–1366.
436 <https://doi.org/10.1177/0898264316661390>.
- 437 [26] K. Ly, C. Walker, S. Berry, R. Snell, E. Marks, Z. Thayer, P. Atatoa-Carr, S. Morton,
438 Telomere length in early childhood is associated with sex and ethnicity, *Sci Rep*. 9 (2019)
439 10359. <https://doi.org/10.1038/s41598-019-46338-x>.
- 440 [27] G. S, H. Cv, S. Fs, R. R, Decline in telomere length by age and effect modification by gender,
441 allostatic load and comorbidities in National Health and Nutrition Examination Survey (1999-
442 2002), *PloS One*. 14 (2019). <https://doi.org/10.1371/journal.pone.0221690>.
- 443 [28] E.S. Choi, Y.K. Chang, D.H. Lee, J.-H. Ko, I. Lim, H. Bang, J.-H. Kim, Gender-specific
444 associations between quality of life and leukocyte telomere length, *Maturitas*. 107 (2018) 68–
445 70. <https://doi.org/10.1016/j.maturitas.2017.10.008>.
- 446 [29] C.M. Vyas, S. Ogata, C.F. Reynolds, D. Mischoulon, G. Chang, N.R. Cook, J.E. Manson, M.
447 Crous-Bou, I. De Vivo, O.I. Okereke, Telomere length and its relationships with lifestyle and
448 behavioural factors: variations by sex and race/ethnicity, *Age Ageing*. (2020).
449 <https://doi.org/10.1093/ageing/afaa186>.
- 450 [30] S.M. Lynch, M.K. Peek, N. Mitra, K. Ravichandran, C. Branas, E. Spangler, W. Zhou, E.D.
451 Paskett, S. Gehlert, C. DeGraffinreid, T.R. Rebbeck, H. Riethman, Race, Ethnicity,
452 Psychosocial Factors, and Telomere Length in a Multicenter Setting, *PLoS One*. 11 (2016)
453 e0146723. <https://doi.org/10.1371/journal.pone.0146723>.

- 454 [31] S.K. Davis, R. Xu, R.J. Khan, A. Gaye, Adiposity and Leukocyte Telomere Length in US
455 Adults by Sex-Specific Race/Ethnicity: National Health and Nutrition Examination Survey,
456 *Ethn Dis.* 30 (2020) 441–450. <https://doi.org/10.18865/ed.30.3.441>.
- 457 [32] S.C. Hunt, W. Chen, J.P. Gardner, M. Kimura, S.R. Srinivasan, J.H. Eckfeldt, G.S. Berenson,
458 A. Aviv, Leukocyte telomeres are longer in African Americans than in whites: the National
459 Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study, *Aging*
460 *Cell.* 7 (2008) 451–458. <https://doi.org/10.1111/j.1474-9726.2008.00397.x>.
- 461 [33] A. Benetos, J.D. Kark, E. Susser, M. Kimura, R. Sinnreich, W. Chen, T. Steenstrup, K.
462 Christensen, U. Herbig, J. von Bornemann Hjelmberg, S.R. Srinivasan, G.S. Berenson, C.
463 Labat, A. Aviv, Tracking and fixed ranking of leukocyte telomere length across the adult life
464 course, *Aging Cell.* 12 (2013) 615–621. <https://doi.org/10.1111/accel.12086>.
- 465 [34] S. Sabharwal, S. Verhulst, G. Guirguis, J.D. Kark, C. Labat, N.E. Roche, K. Martimucci, K.
466 Patel, D.S. Heller, M. Kimura, D. Chuang, A. Chuang, A. Benetos, A. Aviv, Telomere length
467 dynamics in early life: the blood-and-muscle model, *FASEB J.* 32 (2018) 529–534.
468 <https://doi.org/10.1096/fj.201700630R>.
- 469 [35] A. Benetos, S. Verhulst, C. Labat, T.-P. Lai, N. Girerd, S. Toupance, F. Zannad, P. Rossignol,
470 A. Aviv, Telomere length tracking in children and their parents: implications for adult onset
471 diseases, *FASEB J.* 33 (2019) 14248–14253. <https://doi.org/10.1096/fj.201901275R>.
- 472 [36] S. Tümpel, K.L. Rudolph, The role of telomere shortening in somatic stem cells and tissue
473 aging: lessons from telomerase model systems, *Ann N Y Acad Sci.* 1266 (2012) 28–39.
474 <https://doi.org/10.1111/j.1749-6632.2012.06547.x>.
- 475 [37] P.J. Barnes, Mechanisms of development of multimorbidity in the elderly, *Eur Respir J.* 45
476 (2015) 790–806. <https://doi.org/10.1183/09031936.00229714>.
- 477 [38] G. Aubert, P.M. Lansdorp, Telomeres and aging, *Physiol Rev.* 88 (2008) 557–579.
478 <https://doi.org/10.1152/physrev.00026.2007>.
- 479 [39] H. Saeed, M. Iqtedar, Stem cell function and maintenance - ends that matter: role of telomeres
480 and telomerase, *J Biosci.* 38 (2013) 641–649. <https://doi.org/10.1007/s12038-013-9346-3>.
- 481 [40] E. Sahin, R.A. Depinho, Linking functional decline of telomeres, mitochondria and stem cells
482 during ageing, *Nature.* 464 (2010) 520–528. <https://doi.org/10.1038/nature08982>.
- 483 [41] D. Jurk, C. Wilson, J.F. Passos, F. Oakley, C. Correia-Melo, L. Greaves, G. Saretzki, C. Fox,
484 C. Lawless, R. Anderson, G. Hewitt, S.L. Pender, N. Fullard, G. Nelson, J. Mann, B. van de
485 Sluis, D.A. Mann, T. von Zglinicki, Chronic inflammation induces telomere dysfunction and
486 accelerates ageing in mice, *Nat Commun.* 2 (2014) 4172.
487 <https://doi.org/10.1038/ncomms5172>.
- 488 [42] R.G. Faragher, D. Kipling, How might replicative senescence contribute to human ageing?,
489 *Bioessays.* 20 (1998) 985–991. [https://doi.org/10.1002/\(SICI\)1521-1878\(199812\)20:12<985::AID-BIES4>3.0.CO;2-A](https://doi.org/10.1002/(SICI)1521-1878(199812)20:12<985::AID-BIES4>3.0.CO;2-A).
- 491 [43] J. Zhang, G. Rane, X. Dai, M.K. Shanmugam, F. Arfuso, R.P. Samy, M.K.P. Lai, D. Kappei,
492 A.P. Kumar, G. Sethi, Ageing and the telomere connection: An intimate relationship with
493 inflammation, *Ageing Res Rev.* 25 (2016) 55–69. <https://doi.org/10.1016/j.arr.2015.11.006>.
- 494 [44] S. Toupance, D. Villemonais, D. Germain, A. Gegout-Petit, E. Albuissou, A. Benetos, The
495 individual's signature of telomere length distribution, *Sci Rep.* 9 (2019) 685.
496 <https://doi.org/10.1038/s41598-018-36756-8>.

- 497 [45] Y. Zhan, S. Hägg, Telomere length and cardiovascular disease risk, *Curr Opin Cardiol.* 34
498 (2019) 270–274. <https://doi.org/10.1097/HCO.0000000000000613>.
- 499 [46] R.G. Morgan, S.J. Ives, L.A. Lesniewski, R.M. Cawthon, R.H.I. Andtbacka, R.D. Noyes, R.S.
500 Richardson, A.J. Donato, Age-related telomere uncapping is associated with cellular
501 senescence and inflammation independent of telomere shortening in human arteries, *Am J*
502 *Physiol Heart Circ Physiol.* 305 (2013) H251-258.
503 <https://doi.org/10.1152/ajpheart.00197.2013>.
- 504 [47] S. Toupance, M.G. Stathopoulou, A.M. Petrelis, V. Gorenjak, C. Labat, T.-P. Lai, S. Visvikis-
505 Siest, A. Benetos, TERC Variants Associated with Short Leukocyte Telomeres: Implication of
506 Higher Early Life Leukocyte Telomere Attrition as Assessed by the Blood-and-Muscle Model,
507 *Cells.* 9 (2020). <https://doi.org/10.3390/cells9061360>.
- 508 [48] X. Yuan, M. Dai, D. Xu, Telomere-related Markers for Cancer, *Curr Top Med Chem.* 20
509 (2020) 410–432. <https://doi.org/10.2174/1568026620666200106145340>.
- 510 [49] M. De Vitis, F. Berardinelli, A. Sgura, Telomere Length Maintenance in Cancer: At the
511 Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT), *Int J Mol*
512 *Sci.* 19 (2018). <https://doi.org/10.3390/ijms19020606>.
- 513 [50] M.A. Jafri, S.A. Ansari, M.H. Alqahtani, J.W. Shay, Roles of telomeres and telomerase in
514 cancer, and advances in telomerase-targeted therapies, *Genome Med.* 8 (2016) 69.
515 <https://doi.org/10.1186/s13073-016-0324-x>.
- 516 [51] A. Davidson, B. Diamond, Autoimmune diseases, *N Engl J Med.* 345 (2001) 340–350.
517 <https://doi.org/10.1056/NEJM200108023450506>.
- 518 [52] World Health organisation, Noncommunicable diseases: progress monitor 2020, 2020.
- 519 [53] GBD 2016 Causes of Death Collaborators, Global, regional, and national age-sex specific
520 mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of
521 Disease Study 2016, *Lancet.* 390 (2017) 1151–1210. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(17)32152-9)
522 [6736\(17\)32152-9](https://doi.org/10.1016/S0140-6736(17)32152-9).
- 523 [54] T. Fitzgerald, R. Melsheimer, M.-H. Lafeuille, P. Lefebvre, L. Morrison, K. Woodruff, I. Lin,
524 B. Emond, Switching and Discontinuation Patterns Among Patients Stable on Originator
525 Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab,
526 *Biologics.* 15 (2021) 1–15. <https://doi.org/10.2147/BTT.S285610>.
- 527 [55] E. Vangeli, S. Bakhshi, A. Baker, A. Fisher, D. Bucknor, U. Mrowietz, A.J.K. Östör, L.
528 Peyrin-Biroulet, A.P. Lacerda, J. Weinman, A Systematic Review of Factors Associated with
529 Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases, *Adv Ther.* 32
530 (2015) 983–1028. <https://doi.org/10.1007/s12325-015-0256-7>.
- 531 [56] A. Kuek, B.L. Hazleman, A.J.K. Ostör, Immune-mediated inflammatory diseases (IMIDs) and
532 biologic therapy: a medical revolution, *Postgrad Med J.* 83 (2007) 251–260.
533 <https://doi.org/10.1136/pgmj.2006.052688>.
- 534 [57] B. Truta, E. Wohler, N. Sobreira, L.W. Datta, S.R. Brant, Role of telomere shortening in
535 anticipation of inflammatory bowel disease, *World J Gastrointest Pharmacol Ther.* 11 (2020)
536 69–78. <https://doi.org/10.4292/wjgpt.v11.i4.69>.
- 537 [58] R.A. Risques, L.A. Lai, T.A. Brentnall, L. Li, Z. Feng, J. Gallaher, M.T. Mandelson, J.D.
538 Potter, M.P. Bronner, P.S. Rabinovitch, Ulcerative colitis is a disease of accelerated colon

- 539 aging: evidence from telomere attrition and DNA damage, *Gastroenterology*. 135 (2008) 410–
540 418. <https://doi.org/10.1053/j.gastro.2008.04.008>.
- 541 [59] R.A. Risques, L.A. Lai, C. Himmetoglu, A. Ebaee, L. Li, Z. Feng, M.P. Bronner, B. Al-
542 Lahham, K.V. Kowdley, K.D. Lindor, P.S. Rabinovitch, T.A. Brentnall, Ulcerative colitis-
543 associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation,
544 *Cancer Res*. 71 (2011) 1669–1679. <https://doi.org/10.1158/0008-5472.CAN-10-1966>.
- 545 [60] K.M. Getliffe, D. Al Dulaimi, C. Martin-Ruiz, R.L. Holder, T. von Zglinicki, A. Morris, C.U.
546 Nwokolo, Lymphocyte telomere dynamics and telomerase activity in inflammatory bowel
547 disease: effect of drugs and smoking, *Aliment Pharmacol Ther*. 21 (2005) 121–131.
548 <https://doi.org/10.1111/j.1365-2036.2005.02311.x>.
- 549 [61] N. Da-Silva, R. Arasaradnam, K. Getliffe, E. Sung, Y. Oo, C. Nwokolo, Altered mRNA
550 expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative
551 colitis and Crohn’s disease, *Dig Liver Dis*. 42 (2010) 544–548.
552 <https://doi.org/10.1016/j.dld.2009.12.005>.
- 553 [62] J.J. Salk, A. Bansal, L.A. Lai, D.A. Crispin, C.H. Ussakli, M.S. Horwitz, M.P. Bronner, T.A.
554 Brentnall, L.A. Loeb, P.S. Rabinovitch, R.A. Risques, Clonal expansions and short telomeres
555 are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis, *Inflamm*
556 *Bowel Dis*. 19 (2013) 2593–2602. <https://doi.org/10.1097/MIB.0b013e3182a87640>.
- 557 [63] X. Liu, J. Lin, L. Wang, Z. Zhang, S. Hou, G. Yang, Telomerase activity in peripheral blood
558 mononuclear cells of psoriatic patients correlates with disease severity, *Br J Dermatol*. 158
559 (2008) 637–639. <https://doi.org/10.1111/j.1365-2133.2007.08377.x>.
- 560 [64] K. Wu, N. Higashi, E.R. Hansen, M. Lund, K. Bang, K. Thestrup-Pedersen, Telomerase
561 activity is increased and telomere length shortened in T cells from blood of patients with atopic
562 dermatitis and psoriasis, *J Immunol*. 165 (2000) 4742–4747.
563 <https://doi.org/10.4049/jimmunol.165.8.4742>.
- 564 [65] K. Wu, A. Volke, M. Lund, K. Bang, K. Thestrup-Pedersen, Telomerase activity is
565 spontaneously increased in lymphocytes from patients with atopic dermatitis and correlates
566 with cellular proliferation, *J Dermatol Sci*. 22 (1999) 24–30. [https://doi.org/10.1016/s0923-1811\(99\)00039-0](https://doi.org/10.1016/s0923-1811(99)00039-0).
- 568 [66] M. Tamayo, S. Pérttega, A. Mosquera, M. Rodríguez, F.J. Blanco, J.L. Fernández-Sueiro, J.
569 Gosálvez, J.L. Fernández, Individual telomere length decay in patients with spondyloarthritis,
570 *Mutat Res*. 765 (2014) 1–5. <https://doi.org/10.1016/j.mrfmmm.2014.04.006>.
- 571 [67] S.E. Steer, F.M.K. Williams, B. Kato, J.P. Gardner, P.J. Norman, M.A. Hall, M. Kimura, R.
572 Vaughan, A. Aviv, T.D. Spector, Reduced telomere length in rheumatoid arthritis is
573 independent of disease activity and duration, *Ann Rheum Dis*. 66 (2007) 476–480.
574 <https://doi.org/10.1136/ard.2006.059188>.
- 575 [68] I. Colmegna, A. Diaz-Borjon, H. Fujii, L. Schaefer, J.J. Goronzy, C.M. Weyand, Defective
576 proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in
577 rheumatoid arthritis, *Arthritis Rheum*. 58 (2008) 990–1000. <https://doi.org/10.1002/art.23287>.
- 578 [69] A.Z.A. Dehbi, T.R.D.J. Radstake, J.C.A. Broen, Accelerated telomere shortening in rheumatic
579 diseases: cause or consequence?, *Expert Rev Clin Immunol*. 9 (2013) 1193–1204.
580 <https://doi.org/10.1586/1744666X.2013.850031>.

- 581 [70] H. Fujii, L. Shao, I. Colmegna, J.J. Goronzy, C.M. Weyand, Telomerase insufficiency in
582 rheumatoid arthritis, *Proc Natl Acad Sci U S A.* 106 (2009) 4360–4365.
583 <https://doi.org/10.1073/pnas.0811332106>.
- 584 [71] K.T. Sibille, H. Chen, E.J. Bartley, J. Riley, T.L. Glover, C.D. King, H. Zhang, Y. Cruz-
585 Almeida, B.R. Goodin, A. Sotolongo, M.E. Petrov, M. Herbert, H.W. Bulls, J.C. Edberg, R.
586 Staud, D. Redden, L.A. Bradley, R.B. Fillingim, Accelerated aging in adults with knee
587 osteoarthritis pain: consideration for frequency, intensity, time, and total pain sites, *Pain Rep.* 2
588 (2017) e591. <https://doi.org/10.1097/PR9.0000000000000591>.
- 589 [72] K.T. Sibille, Ó.A. Steingrimsdóttir, R.B. Fillingim, A. Stubhaug, H. Schirmer, H. Chen, B.S.
590 McEwen, C.S. Nielsen, Investigating the Burden of Chronic Pain: An Inflammatory and
591 Metabolic Composite, *Pain Res Manag.* 2016 (2016) 7657329.
592 <https://doi.org/10.1155/2016/7657329>.
- 593 [73] N. Vazirpanah, F.H. Verhagen, A. Rothova, T.O.A.R. Missotten, M. van Velthoven, A.I. Den
594 Hollander, C.B. Hoyng, T.R.D.J. Radstake, J.C.A. Broen, J.J.W. Kuiper, Aberrant leukocyte
595 telomere length in Birdshot Uveitis, *PLoS One.* 12 (2017) e0176175.
596 <https://doi.org/10.1371/journal.pone.0176175>.
- 597 [74] R.J. O’Sullivan, J. Karlseder, Telomeres: protecting chromosomes against genome instability,
598 *Nat Rev Mol Cell Biol.* 11 (2010) 171–181. <https://doi.org/10.1038/nrm2848>.
- 599 [75] T. de Lange, Shelterin-Mediated Telomere Protection, *Annu Rev Genet.* 52 (2018) 223–247.
600 <https://doi.org/10.1146/annurev-genet-032918-021921>.
- 601 [76] J.D. Griffith, L. Comeau, S. Rosenfield, R.M. Stansel, A. Bianchi, H. Moss, T. de Lange,
602 Mammalian telomeres end in a large duplex loop, *Cell.* 97 (1999) 503–514.
603 [https://doi.org/10.1016/s0092-8674\(00\)80760-6](https://doi.org/10.1016/s0092-8674(00)80760-6).
- 604 [77] A. Sfeir, T. de Lange, Removal of shelterin reveals the telomere end-protection problem,
605 *Science.* 336 (2012) 593–597. <https://doi.org/10.1126/science.1218498>.
- 606 [78] A.M. Olovnikov, A theory of marginotomy. The incomplete copying of template margin in
607 enzymic synthesis of polynucleotides and biological significance of the phenomenon, *J Theor*
608 *Biol.* 41 (1973) 181–190. [https://doi.org/10.1016/0022-5193\(73\)90198-7](https://doi.org/10.1016/0022-5193(73)90198-7).
- 609 [79] R.J. Wellinger, In the end, what’s the problem?, *Mol Cell.* 53 (2014) 855–856.
610 <https://doi.org/10.1016/j.molcel.2014.03.008>.
- 611 [80] R. Ohki, T. Tsurimoto, F. Ishikawa, In vitro reconstitution of the end replication problem, *Mol*
612 *Cell Biol.* 21 (2001) 5753–5766. <https://doi.org/10.1128/mcb.21.17.5753-5766.2001>.
- 613 [81] A.Y. Aksenova, S.M. Mirkin, At the Beginning of the End and in the Middle of the Beginning:
614 Structure and Maintenance of Telomeric DNA Repeats and Interstitial Telomeric Sequences,
615 *Genes (Basel).* 10 (2019). <https://doi.org/10.3390/genes10020118>.
- 616 [82] R. Salama, M. Sadaie, M. Hoare, M. Narita, Cellular senescence and its effector programs,
617 *Genes Dev.* 28 (2014) 99–114. <https://doi.org/10.1101/gad.235184.113>.
- 618 [83] Y.-S. Cong, W.E. Wright, J.W. Shay, Human telomerase and its regulation, *Microbiol Mol*
619 *Biol Rev.* 66 (2002) 407–425, table of contents. [https://doi.org/10.1128/mmbr.66.3.407-](https://doi.org/10.1128/mmbr.66.3.407-425.2002)
620 [425.2002](https://doi.org/10.1128/mmbr.66.3.407-425.2002).
- 621 [84] S.A. Stewart, R.A. Weinberg, Telomerase and human tumorigenesis, *Semin Cancer Biol.* 10
622 (2000) 399–406. <https://doi.org/10.1006/scbi.2000.0339>.

- 623 [85] L. Harrington, Biochemical aspects of telomerase function, *Cancer Lett.* 194 (2003) 139–154.
624 [https://doi.org/10.1016/s0304-3835\(02\)00701-2](https://doi.org/10.1016/s0304-3835(02)00701-2).
- 625 [86] P.P. Schrumpfová, J. Fajkus, Composition and Function of Telomerase—A Polymerase
626 Associated with the Origin of Eukaryotes, *Biomolecules.* 10 (2020).
627 <https://doi.org/10.3390/biom10101425>.
- 628 [87] J.W. Shay, S. Bacchetti, A survey of telomerase activity in human cancer, *Eur J Cancer.* 33
629 (1997) 787–791. [https://doi.org/10.1016/S0959-8049\(97\)00062-2](https://doi.org/10.1016/S0959-8049(97)00062-2).
- 630 [88] N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L. Ho, G.M. Coviello,
631 W.E. Wright, S.L. Weinrich, J.W. Shay, Specific association of human telomerase activity
632 with immortal cells and cancer, *Science.* 266 (1994) 2011–2015.
633 <https://doi.org/10.1126/science.7605428>.
- 634 [89] C.P. Morales, S.E. Holt, M. Ouellette, K.J. Kaur, Y. Yan, K.S. Wilson, M.A. White, W.E.
635 Wright, J.W. Shay, Absence of cancer-associated changes in human fibroblasts immortalized
636 with telomerase, *Nat Genet.* 21 (1999) 115–118. <https://doi.org/10.1038/50663>.
- 637 [90] J.W. Shay, W.E. Wright, H. Werbin, Defining the molecular mechanisms of human cell
638 immortalization, *Biochim Biophys Acta.* 1072 (1991) 1–7. [https://doi.org/10.1016/0304-419x\(91\)90003-4](https://doi.org/10.1016/0304-419x(91)90003-4).
- 640 [91] J.W. Shay, Role of Telomeres and Telomerase in Aging and Cancer, *Cancer Discov.* 6 (2016)
641 584–593. <https://doi.org/10.1158/2159-8290.CD-16-0062>.
- 642 [92] J. Maciejowski, T. de Lange, Telomeres in cancer: tumour suppression and genome instability,
643 *Nat Rev Mol Cell Biol.* 18 (2017) 175–186. <https://doi.org/10.1038/nrm.2016.171>.
- 644 [93] P.J. Hohensinner, J.J. Goronzy, C.M. Weyand, Telomere dysfunction, autoimmunity and
645 aging, *Aging Dis.* 2 (2011) 524–537.
- 646 [94] R.W. Frenck, E.H. Blackburn, K.M. Shannon, The rate of telomere sequence loss in human
647 leukocytes varies with age, *Proc Natl Acad Sci U S A.* 95 (1998) 5607–5610.
648 <https://doi.org/10.1073/pnas.95.10.5607>.
- 649 [95] K. Okuda, A. Bardeguet, J.P. Gardner, P. Rodriguez, V. Ganesh, M. Kimura, J. Skurnick, G.
650 Awad, A. Aviv, Telomere length in the newborn, *Pediatr Res.* 52 (2002) 377–381.
651 <https://doi.org/10.1203/00006450-200209000-00012>.
- 652 [96] G. Aubert, G.M. Baerlocher, I. Vulto, S.S. Poon, P.M. Lansdorp, Collapse of telomere
653 homeostasis in hematopoietic cells caused by heterozygous mutations in telomerase genes,
654 *PLoS Genet.* 8 (2012) e1002696. <https://doi.org/10.1371/journal.pgen.1002696>.
- 655 [97] E.M. Bijmens, M.P. Zeegers, C. Derom, D.S. Martens, M. Gielen, G.J. Hageman, M. Plusquin,
656 E. Thiery, R. Vlietinck, T.S. Nawrot, Telomere tracking from birth to adulthood and
657 residential traffic exposure, *BMC Med.* 15 (2017) 205. <https://doi.org/10.1186/s12916-017-0964-8>.
- 659 [98] V. Gorenjak, A.M. Petrelis, M.G. Stathopoulou, S. Visvikis-Siest, Telomere length
660 determinants in childhood, *Clin Chem Lab Med.* 58 (2020) 162–177.
661 <https://doi.org/10.1515/cclm-2019-0235>.
- 662 [99] D.S. Martens, C. Van Der Stukken, C. Derom, E. Thiery, E.M. Bijmens, T.S. Nawrot, Newborn
663 telomere length predicts later life telomere length: Tracking telomere length from birth to
664 child- and adulthood, *EBioMedicine.* 63 (2021) 103164.
665 <https://doi.org/10.1016/j.ebiom.2020.103164>.

- 666 [100] K.S. de Fluiter, V. Codd, M. Denniff, G.F. Kerkhof, I.A.L.P. van Beijsterveldt, L.M. Breij,
667 N.J. Samani, M. Abrahamse-Berkeveld, A.C.S. Hokken-Koelega, Longitudinal telomere
668 length and body composition in healthy term-born infants during the first two years of life,
669 PLoS One. 16 (2021) e0246400. <https://doi.org/10.1371/journal.pone.0246400>.
- 670 [101] D.S. Martens, M. Plusquin, W. Gyselaers, I. De Vivo, T.S. Nawrot, Maternal pre-pregnancy
671 body mass index and newborn telomere length, BMC Med. 14 (2016) 148.
672 <https://doi.org/10.1186/s12916-016-0689-0>.
- 673 [102] G. Verner, E. Epel, M. Lahti-Pulkkinen, E. Kajantie, C. Buss, J. Lin, E. Blackburn, K.
674 Räikkönen, P.D. Wadhwa, S. Entringer, Maternal Psychological Resilience During Pregnancy
675 and Newborn Telomere Length: A Prospective Study, Am J Psychiatry. 178 (2021) 183–192.
676 <https://doi.org/10.1176/appi.ajp.2020.19101003>.
- 677 [103] M. Bosquet Enlow, C.R. Petty, M.R. Hacker, H.H. Burris, Maternal psychosocial functioning,
678 obstetric health history, and newborn telomere length, Psychoneuroendocrinology. 123 (2021)
679 105043. <https://doi.org/10.1016/j.psyneuen.2020.105043>.
- 680 [104] S. Entringer, E.S. Epel, J. Lin, C. Buss, B. Shahbaba, E.H. Blackburn, H.N. Simhan, P.D.
681 Wadhwa, Maternal psychosocial stress during pregnancy is associated with newborn leukocyte
682 telomere length, Am J Obstet Gynecol. 208 (2013) 134.e1–7.
683 <https://doi.org/10.1016/j.ajog.2012.11.033>.
- 684 [105] B. Liu, L. Song, L. Zhang, M. Wu, L. Wang, Z. Cao, C. Xiong, B. Zhang, Y. Li, W. Xia, S.
685 Xu, Y. Wang, Prenatal second-hand smoke exposure and newborn telomere length, Pediatr
686 Res. 87 (2020) 1081–1085. <https://doi.org/10.1038/s41390-019-0594-2>.
- 687 [106] H. Mirzakhani, I. De Vivo, J.S. Leeder, R. Gaedigk, C.A. Vyhlidal, S.T. Weiss, K. Tantisira,
688 Early pregnancy intrauterine fetal exposure to maternal smoking and impact on fetal telomere
689 length, Eur J Obstet Gynecol Reprod Biol. 218 (2017) 27–32.
690 <https://doi.org/10.1016/j.ejogrb.2017.09.013>.
- 691 [107] T.S. Send, M. Gilles, V. Codd, I. Wolf, S. Bardtke, F. Streit, J. Strohmaier, J. Frank, D.
692 Schendel, M.W. Sütterlin, M. Denniff, M. Laucht, N.J. Samani, M. Deuschle, M. Rietschel,
693 S.H. Witt, Telomere Length in Newborns is Related to Maternal Stress During Pregnancy,
694 Neuropsychopharmacology. 42 (2017) 2407–2413. <https://doi.org/10.1038/npp.2017.73>.
- 695 [108] P. Ip, B.H.Y. Chung, F.K.W. Ho, G.C.F. Chan, W. Deng, W.H.S. Wong, S.L. Lee, P.Y.T.
696 Chan, D. Ying, W.L. Wong, K.T.S. Tung, Y.L. Lau, Prenatal Tobacco Exposure Shortens
697 Telomere Length in Children, Nicotine Tob Res. 19 (2017) 111–118.
698 <https://doi.org/10.1093/ntr/ntw139>.
- 699 [109] K.O. Myers, B. Ibrahimou, K.K. Yusuf, D.E. Mauck, H.M. Salihu, The effect of maternal
700 vitamin C intake on fetal telomere length, J Matern Fetal Neonatal Med. 34 (2021) 1143–1148.
701 <https://doi.org/10.1080/14767058.2019.1628940>.
- 702 [110] S. Entringer, E.S. Epel, J. Lin, E.H. Blackburn, C. Buss, B. Shahbaba, D.L. Gillen, R.
703 Venkataramanan, H.N. Simhan, P.D. Wadhwa, Maternal Folate Concentration in Early
704 Pregnancy and Newborn Telomere Length, Ann Nutr Metab. 66 (2015) 202–208.
705 <https://doi.org/10.1159/000381925>.
- 706 [111] J.-H. Kim, G.J. Kim, D. Lee, J.-H. Ko, I. Lim, H. Bang, B.W. Koes, B. Seong, D.-C. Lee,
707 Higher maternal vitamin D concentrations are associated with longer leukocyte telomeres in
708 newborns, Matern Child Nutr. 14 (2018). <https://doi.org/10.1111/mcn.12475>.

- 709 [112] B. Wei, Y. Shao, J. Liang, P. Tang, M. Mo, B. Liu, H. Huang, H.J.J. Tan, D. Huang, S. Liu, X.
710 Qiu, Maternal overweight but not paternal overweight before pregnancy is associated with
711 shorter newborn telomere length: evidence from Guangxi Zhuang birth cohort in China, *BMC*
712 *Pregnancy Childbirth*. 21 (2021) 283. <https://doi.org/10.1186/s12884-021-03757-x>.
- 713 [113] Z. Verde, L. Reinoso-Barbero, L. Chicharro, N. Garatachea, P. Resano, I. Sánchez-Hernández,
714 J.M. Rodríguez González-Moro, F. Bandrés, C. Santiago, F. Gómez-Gallego, Effects of
715 cigarette smoking and nicotine metabolite ratio on leukocyte telomere length, *Environ Res*.
716 140 (2015) 488–494. <https://doi.org/10.1016/j.envres.2015.05.008>.
- 717 [114] A. Müezziner, U. Mons, A.K. Dieffenbach, K. Butterbach, K.-U. Saum, M. Schick, H.
718 Stammer, P. Boukamp, B. Holleczer, C. Stegmaier, H. Brenner, Smoking habits and leukocyte
719 telomere length dynamics among older adults: Results from the ESTHER cohort, *Exp*
720 *Gerontol*. 70 (2015) 18–25. <https://doi.org/10.1016/j.exger.2015.07.002>.
- 721 [115] A.M. Valdes, T. Andrew, J.P. Gardner, M. Kimura, E. Oelsner, L.F. Cherkas, A. Aviv, T.D.
722 Spector, Obesity, cigarette smoking, and telomere length in women, *Lancet*. 366 (2005) 662–
723 664. [https://doi.org/10.1016/S0140-6736\(05\)66630-5](https://doi.org/10.1016/S0140-6736(05)66630-5).
- 724 [116] S. Reichert, A. Stier, Does oxidative stress shorten telomeres in vivo? A review, *Biol Lett*. 13
725 (2017). <https://doi.org/10.1098/rsbl.2017.0463>.
- 726 [117] T.E. Strandberg, O. Saijonmaa, R.S. Tilvis, K.H. Pitkälä, A.Y. Strandberg, T.A. Miettinen, F.
727 Fyhrquist, Association of telomere length in older men with mortality and midlife body mass
728 index and smoking, *J Gerontol A Biol Sci Med Sci*. 66 (2011) 815–820.
729 <https://doi.org/10.1093/gerona/qlr064>.
- 730 [118] J. Huzen, L.S.M. Wong, D.J. van Veldhuisen, N.J. Samani, A.H. Zwinderman, V. Codd, R.M.
731 Cawthon, G.F.J.D. Benus, I.C.C. van der Horst, G. Navis, S.J.L. Bakker, R.T. Gansevoort,
732 P.E. de Jong, H.L. Hillege, W.H. van Gilst, R.A. de Boer, P. van der Harst, Telomere length
733 loss due to smoking and metabolic traits, *J Intern Med*. 275 (2014) 155–163.
734 <https://doi.org/10.1111/joim.12149>.
- 735 [119] X. Chen, J.C. Velez, C. Barbosa, M. Pepper, A. Andrade, L. Stoner, I. De Vivo, B. Gelaye,
736 M.A. Williams, Smoking and perceived stress in relation to short salivary telomere length
737 among caregivers of children with disabilities, *Stress*. 18 (2015) 20–28.
738 <https://doi.org/10.3109/10253890.2014.969704>.
- 739 [120] Y. Astuti, A. Wardhana, J. Watkins, W. Wulaningsih, PILAR Research Network, Cigarette
740 smoking and telomere length: A systematic review of 84 studies and meta-analysis, *Environ*
741 *Res*. 158 (2017) 480–489. <https://doi.org/10.1016/j.envres.2017.06.038>.
- 742 [121] M. Morlá, X. Busquets, J. Pons, J. Sauleda, W. MacNee, A.G.N. Agustí, Telomere shortening
743 in smokers with and without COPD, *Eur Respir J*. 27 (2006) 525–528.
744 <https://doi.org/10.1183/09031936.06.00087005>.
- 745 [122] R.J. Khan, S.Y. Gebreab, A. Gaye, P.R. Crespo, R. Xu, S.K. Davis, Associations of smoking
746 indicators and cotinine levels with telomere length: National Health and Nutrition Examination
747 Survey, *Prev Med Rep*. 15 (2019) 100895. <https://doi.org/10.1016/j.pmedr.2019.100895>.
- 748 [123] L. Mirabello, W.-Y. Huang, J.Y.Y. Wong, N. Chatterjee, D. Reding, E.D. Crawford, I. De
749 Vivo, R.B. Hayes, S.A. Savage, The association between leukocyte telomere length and
750 cigarette smoking, dietary and physical variables, and risk of prostate cancer, *Aging Cell*. 8
751 (2009) 405–413. <https://doi.org/10.1111/j.1474-9726.2009.00485.x>.

- 752 [124] M. Weischer, S.E. Bojesen, B.G. Nordestgaard, Telomere shortening unrelated to smoking,
753 body weight, physical activity, and alcohol intake: 4,576 general population individuals with
754 repeat measurements 10 years apart, *PLoS Genet.* 10 (2014) e1004191.
755 <https://doi.org/10.1371/journal.pgen.1004191>.
- 756 [125] M. Bateson, A. Aviv, L. Bendix, A. Benetos, Y. Ben-Shlomo, S.E. Bojesen, C. Cooper, R.
757 Cooper, I.J. Deary, S. Hägg, S.E. Harris, J.D. Kark, F. Kronenberg, D. Kuh, C. Labat, C.M.
758 Martin-Ruiz, C. Meyer, B.G. Nordestgaard, B.W.J.H. Penninx, G.V. Pepper, D. Révész, M.A.
759 Said, J.M. Starr, H. Syddall, W.M. Thomson, P. van der Harst, M. Whooley, T. von Zglinicki,
760 P. Willeit, Y. Zhan, D. Nettle, Smoking does not accelerate leucocyte telomere attrition: a
761 meta-analysis of 18 longitudinal cohorts, *R Soc Open Sci.* 6 (2019) 190420.
762 <https://doi.org/10.1098/rsos.190420>.
- 763 [126] J. Adams, C. Martin-Ruiz, M.S. Pearce, M. White, L. Parker, T. von Zglinicki, No association
764 between socio-economic status and white blood cell telomere length, *Aging Cell.* 6 (2007)
765 125–128. <https://doi.org/10.1111/j.1474-9726.2006.00258.x>.
- 766 [127] H. Satoh, K. Hiyama, M. Takeda, Y. Awaya, K. Watanabe, Y. Ihara, H. Maeda, S. Ishioka, M.
767 Yamakido, Telomere shortening in peripheral blood cells was related with aging but not with
768 white blood cell count, *Jpn J Hum Genet.* 41 (1996) 413–417.
769 <https://doi.org/10.1007/BF01876332>.
- 770 [128] C. Bischoff, H.C. Petersen, J. Graakjaer, K. Andersen-Ranberg, J.W. Vaupel, V.A. Bohr, S.
771 Kølvrå, K. Christensen, No association between telomere length and survival among the
772 elderly and oldest old, *Epidemiology.* 17 (2006) 190–194.
773 <https://doi.org/10.1097/01.ede.0000199436.55248.10>.
- 774 [129] K. Nordfjäll, M. Eliasson, B. Stegmayr, O. Melander, P. Nilsson, G. Roos, Telomere length is
775 associated with obesity parameters but with a gender difference, *Obesity (Silver Spring).* 16
776 (2008) 2682–2689. <https://doi.org/10.1038/oby.2008.413>.
- 777 [130] A. Cassidy, I. De Vivo, Y. Liu, J. Han, J. Prescott, D.J. Hunter, E.B. Rimm, Associations
778 between diet, lifestyle factors, and telomere length in women¹²³, *Am J Clin Nutr.* 91 (2010)
779 1273–1280. <https://doi.org/10.3945/ajcn.2009.28947>.
- 780 [131] V. Boccardi, A. Esposito, M.R. Rizzo, R. Marfella, M. Barbieri, G. Paolisso, Mediterranean
781 diet, telomere maintenance and health status among elderly, *PLoS One.* 8 (2013) e62781.
782 <https://doi.org/10.1371/journal.pone.0062781>.
- 783 [132] Q. Xu, C.G. Parks, L.A. DeRoo, R.M. Cawthon, D.P. Sandler, H. Chen, Multivitamin use and
784 telomere length in women¹²³, *Am J Clin Nutr.* 89 (2009) 1857–1863.
785 <https://doi.org/10.3945/ajcn.2008.26986>.
- 786 [133] M. Crous-Bou, T.T. Fung, J. Prescott, B. Julin, M. Du, Q. Sun, K.M. Rexrode, F.B. Hu, I. De
787 Vivo, Mediterranean diet and telomere length in Nurses' Health Study: population based
788 cohort study, *BMJ.* 349 (2014) g6674. <https://doi.org/10.1136/bmj.g6674>.
- 789 [134] C.W. Leung, B.A. Laraia, B.L. Needham, D.H. Rehkopf, N.E. Adler, J. Lin, E.H. Blackburn,
790 E.S. Epel, Soda and cell aging: associations between sugar-sweetened beverage consumption
791 and leukocyte telomere length in healthy adults from the National Health and Nutrition
792 Examination Surveys, *Am J Public Health.* 104 (2014) 2425–2431.
793 <https://doi.org/10.2105/AJPH.2014.302151>.
- 794 [135] M.J. Navarro-Ibarra, J. Hernández, G. Caire-Juvera, Diet, physical activity and telomere length
795 in adults., *Nutr Hosp.* 36 (2019) 1403–1417. <https://doi.org/10.20960/nh.02673>.

- 796 [136] L.F. Cherkas, J.L. Hunkin, B.S. Kato, J.B. Richards, J.P. Gardner, G.L. Surdulescu, M.
797 Kimura, X. Lu, T.D. Spector, A. Aviv, The association between physical activity in leisure
798 time and leukocyte telomere length, *Arch Intern Med.* 168 (2008) 154–158.
799 <https://doi.org/10.1001/archinternmed.2007.39>.
- 800 [137] M. Du, J. Prescott, P. Kraft, J. Han, E. Giovannucci, S.E. Hankinson, I. De Vivo, Physical
801 activity, sedentary behavior, and leukocyte telomere length in women, *Am J Epidemiol.* 175
802 (2012) 414–422. <https://doi.org/10.1093/aje/kwr330>.
- 803 [138] N.C. Arsenis, T. You, E.F. Ogawa, G.M. Tinsley, L. Zuo, Physical activity and telomere
804 length: Impact of aging and potential mechanisms of action, *Oncotarget.* 8 (2017) 45008–
805 45019. <https://doi.org/10.18632/oncotarget.16726>.
- 806 [139] D.E. Rae, A. Vignaud, G.S. Butler-Browne, L.-E. Thornell, C. Sinclair-Smith, E.W. Derman,
807 M.I. Lambert, M. Collins, Skeletal muscle telomere length in healthy, experienced, endurance
808 runners, *Eur J Appl Physiol.* 109 (2010) 323–330. <https://doi.org/10.1007/s00421-010-1353-6>.
- 809 [140] I.B.Ø. Østhus, A. Sgura, F. Berardinelli, I.V. Alsnes, E. Brønstad, T. Rehn, P.K. Støbakk, H.
810 Hatle, U. Wisløff, J. Nauman, Telomere Length and Long-Term Endurance Exercise: Does
811 Exercise Training Affect Biological Age? A Pilot Study, *PLoS One.* 7 (2012).
812 <https://doi.org/10.1371/journal.pone.0052769>.
- 813 [141] J. Denham, C.P. Nelson, B.J. O'Brien, S.A. Nankervis, M. Denniff, J.T. Harvey, F.Z.
814 Marques, V. Codd, E. Zukowska-Szczechowska, N.J. Samani, M. Tomaszewski, F.J.
815 Charchar, Longer Leukocyte Telomeres Are Associated with Ultra-Endurance Exercise
816 Independent of Cardiovascular Risk Factors, *PLoS One.* 8 (2013).
817 <https://doi.org/10.1371/journal.pone.0069377>.
- 818 [142] L.C.R. Silva, A.L. de Araújo, J.R. Fernandes, M. de S.T. Matias, P.R. Silva, A.J.S. Duarte,
819 L.E. Garcez Leme, G. Benard, Moderate and intense exercise lifestyles attenuate the effects of
820 aging on telomere length and the survival and composition of T cell subpopulations, *Age*
821 (Dordr). 38 (2016). <https://doi.org/10.1007/s11357-016-9879-0>.
- 822 [143] A.T. LUDLOW, J.B. ZIMMERMAN, S. WITKOWSKI, J.W. HEARN, B.D. HATFIELD,
823 S.M. ROTH, Relationship between Physical Activity Level, Telomere Length, and Telomerase
824 Activity, *Med Sci Sports Exerc.* 40 (2008) 1764–1771.
825 <https://doi.org/10.1249/MSS.0b013e31817c92aa>.
- 826 [144] T.J. LaRocca, D.R. Seals, G.L. Pierce, Leukocyte Telomere Length is Preserved with Aging in
827 Endurance Exercise-Trained Adults and Related to Maximal Aerobic Capacity, *Mech Ageing*
828 *Dev.* 131 (2010) 165–167. <https://doi.org/10.1016/j.mad.2009.12.009>.
- 829 [145] J. Krauss, R. Farzaneh-Far, E. Puterman, B. Na, J. Lin, E. Epel, E. Blackburn, M.A. Whooley,
830 Physical Fitness and Telomere Length in Patients with Coronary Heart Disease: Findings from
831 the Heart and Soul Study, *PLoS One.* 6 (2011). <https://doi.org/10.1371/journal.pone.0026983>.
- 832 [146] J.-H. Kim, J.-H. Ko, D. Lee, I. Lim, H. Bang, Habitual physical exercise has beneficial effects
833 on telomere length in postmenopausal women, *Menopause.* 19 (2012) 1109–1115.
834 <https://doi.org/10.1097/gme.0b013e3182503e97>.
- 835 [147] A. Borghini, G. Giardini, A. Tonacci, F. Mastorci, A. Mercuri, S. Mrakic-Sposta, S.M. Sposta,
836 S. Moretti, M.G. Andreassi, L. Pratali, Chronic and acute effects of endurance training on
837 telomere length, *Mutagenesis.* 30 (2015) 711–716. <https://doi.org/10.1093/mutage/gev038>.

- 838 [148] L. Soares-Miranda, F. Imamura, D. Siscovick, N.S. Jenny, A.L. Fitzpatrick, D. Mozaffarian,
839 Physical Activity, Physical Fitness and Leukocyte Telomere Length: the Cardiovascular
840 Health Study., *Med Sci Sports Exerc.* 47 (2015) 2525–2534.
841 <https://doi.org/10.1249/MSS.0000000000000720>.
- 842 [149] C. Welendorf, C.F. Nicoletti, M.A. de S. Pinhel, N.Y. Noronha, B.M.F. de Paula, C.B. Nonino,
843 Obesity, weight loss, and influence on telomere length: New insights for personalized
844 nutrition, *Nutrition.* 66 (2019) 115–121. <https://doi.org/10.1016/j.nut.2019.05.002>.
- 845 [150] E. Mundstock, E.E. Sarria, H. Zatti, F. Mattos Louzada, L. Kich Grun, M. Herbert Jones,
846 F.T.C.R. Guma, J. Mazzola In Memoriam, M. Epifanio, R.T. Stein, F.M. Barbé-Tuana, R.
847 Mattiello, Effect of obesity on telomere length: Systematic review and meta-analysis, *Obesity*
848 (Silver Spring). 23 (2015) 2165–2174. <https://doi.org/10.1002/oby.21183>.
- 849 [151] S. Kim, C.G. Parks, L.A. DeRoo, H. Chen, J.A. Taylor, R.M. Cawthon, D.P. Sandler, Obesity
850 and weight gain in adulthood and telomere length, *Cancer Epidemiol Biomarkers Prev.* 18
851 (2009) 816–820. <https://doi.org/10.1158/1055-9965.EPI-08-0935>.
- 852 [152] J.A. Batsis, T.A. Mackenzie, E. Vasquez, C.M. Germain, R.T. Emeny, P. Rippberger, F.
853 Lopez-Jimenez, S.J. Bartels, Association of adiposity, telomere length and mortality: data from
854 the NHANES 1999-2002, *Int J Obes (Lond).* 42 (2018) 198–204.
855 <https://doi.org/10.1038/ijo.2017.202>.
- 856 [153] M. Lee, H. Martin, M.A. Firpo, E.W. Demerath, Inverse association between adiposity and
857 telomere length: The Fels Longitudinal Study, *Am J Hum Biol.* 23 (2011) 100–106.
858 <https://doi.org/10.1002/ajhb.21109>.
- 859 [154] H. Zhu, X. Wang, B. Gutin, C.L. Davis, D. Keeton, J. Thomas, I. Stallmann-Jorgensen, G.
860 Mookken, V. Bundy, H. Snieder, P. van der Harst, Y. Dong, Leukocyte telomere length in
861 healthy Caucasian and African-American adolescents: relationships with race, sex, adiposity,
862 adipokines, and physical activity, *J Pediatr.* 158 (2011) 215–220.
863 <https://doi.org/10.1016/j.jpeds.2010.08.007>.
- 864 [155] T. Tibbs, D. Haire-Joshu, K.B. Schechtman, R.C. Brownson, M.S. Nanney, C. Houston, W.
865 Auslander, The relationship between parental modeling, eating patterns, and dietary intake
866 among African-American parents, *J Am Diet Assoc.* 101 (2001) 535–541.
867 [https://doi.org/10.1016/S0002-8223\(01\)00134-1](https://doi.org/10.1016/S0002-8223(01)00134-1).
- 868 [156] E.M. Arredondo, J.P. Elder, G.X. Ayala, N. Campbell, B. Baquero, S. Duerksen, Is parenting
869 style related to children’s healthy eating and physical activity in Latino families?, *Health Educ*
870 *Res.* 21 (2006) 862–871. <https://doi.org/10.1093/her/cyl110>.
- 871 [157] T. Østbye, R. Malhotra, M. Stroo, C. Lovelady, R. Brouwer, N. Zucker, B. Fuemmeler, The
872 effect of the home environment on physical activity and dietary intake in preschool children,
873 *Int J Obes (Lond).* 37 (2013) 1314–1321. <https://doi.org/10.1038/ijo.2013.76>.
- 874 [158] K.J. Webber, L.J. Loescher, A systematic review of parent role modeling of healthy eating and
875 physical activity for their young African American children, *J Spec Pediatr Nurs.* 18 (2013)
876 173–188. <https://doi.org/10.1111/jspn.12033>.
- 877 [159] A.B. Lloyd, D.R. Lubans, R.C. Plotnikoff, P.J. Morgan, Paternal Lifestyle-Related Parenting
878 Practices Mediate Changes in Children’s Dietary and Physical Activity Behaviors: Findings
879 From the Healthy Dads, Healthy Kids Community Randomized Controlled Trial, *J Phys Act*
880 *Health.* 12 (2015) 1327–1335. <https://doi.org/10.1123/jpah.2014-0367>.

- 881 [160] A. Ochoa, J.M. Berge, Home Environmental Influences on Childhood Obesity in the Latino
882 Population: A Decade Review of Literature, *J Immigr Minor Health*. 19 (2017) 430–447.
883 <https://doi.org/10.1007/s10903-016-0539-3>.
- 884 [161] A.C. Lindsay, S.F. Wallington, F.D. Lees, M.L. Greaney, Exploring How the Home
885 Environment Influences Eating and Physical Activity Habits of Low-Income, Latino Children
886 of Predominantly Immigrant Families: A Qualitative Study, *Int J Environ Res Public Health*.
887 15 (2018). <https://doi.org/10.3390/ijerph15050978>.
- 888 [162] E. Stamatakis, P. Primatesta, S. Chinn, R. Rona, E. Falaschetti, Overweight and obesity trends
889 from 1974 to 2003 in English children: what is the role of socioeconomic factors?, *Arch Dis*
890 *Child*. 90 (2005) 999–1004. <https://doi.org/10.1136/adc.2004.068932>.
- 891 [163] R.D. Conger, K.J. Conger, M.J. Martin, Socioeconomic Status, Family Processes, and
892 Individual Development, *J Marriage Fam*. 72 (2010) 685–704. [https://doi.org/10.1111/j.1741-](https://doi.org/10.1111/j.1741-3737.2010.00725.x)
893 [3737.2010.00725.x](https://doi.org/10.1111/j.1741-3737.2010.00725.x).
- 894 [164] R.D. Mare, A multigenerational view of inequality, *Demography*. 48 (2011) 1–23.
895 <https://doi.org/10.1007/s13524-011-0014-7>.
- 896 [165] R.D. Mare, MULTIGENERATIONAL ASPECTS OF SOCIAL STRATIFICATION: ISSUES
897 FOR FURTHER RESEARCH, *Res Soc Stratif Mobil*. 35 (2014) 121–128.
898 <https://doi.org/10.1016/j.rssm.2014.01.004>.
- 899 [166] E.J. Pantesco, D.K. Leibel, J.J. Ashe, S.R. Waldstein, L.I. Katzel, H.B. Liu, N.-P. Weng, M.K.
900 Evans, A.B. Zonderman, D.L. Beatty Moody, Multiple forms of discrimination, social status,
901 and telomere length: Interactions within race, *Psychoneuroendocrinology*. 98 (2018) 119–126.
902 <https://doi.org/10.1016/j.psyneuen.2018.08.012>.
- 903 [167] D.L. Beatty Moody, D.K. Leibel, T.M. Darden, J.J. Ashe, S.R. Waldstein, L.I. Katzel, H.B.
904 Liu, N.-P. Weng, M.K. Evans, A.B. Zonderman, Interpersonal-level discrimination indices,
905 sociodemographic factors, and telomere length in African-Americans and Whites, *Biol*
906 *Psychol*. 141 (2019) 1–9. <https://doi.org/10.1016/j.biopsycho.2018.12.004>.
- 907 [168] N. Yamada, Telomere shortening, atherosclerosis, and metabolic syndrome, *Intern Med*. 42
908 (2003) 135–136. <https://doi.org/10.2169/internalmedicine.42.135>.
- 909 [169] M.Y. Armanios, J.J.-L. Chen, J.D. Cogan, J.K. Alder, R.G. Ingersoll, C. Markin, W.E.
910 Lawson, M. Xie, I. Vulto, J.A. Phillips, P.M. Lansdorp, C.W. Greider, J.E. Loyd, Telomerase
911 mutations in families with idiopathic pulmonary fibrosis, *N Engl J Med*. 356 (2007) 1317–
912 1326. <https://doi.org/10.1056/NEJMoa066157>.
- 913 [170] A.M. Clark, M. DesMeules, W. Luo, A.S. Duncan, A. Wielgosz, Socioeconomic status and
914 cardiovascular disease: risks and implications for care, *Nat Rev Cardiol*. 6 (2009) 712–722.
915 <https://doi.org/10.1038/nrcardio.2009.163>.
- 916 [171] P. Willeit, J. Raschenberger, E.E. Heydon, S. Tsimikas, M. Haun, A. Mayr, S. Weger, J.L.
917 Witztum, A.S. Butterworth, J. Willeit, F. Kronenberg, S. Kiechl, Leucocyte telomere length
918 and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-
919 analysis, *PLoS One*. 9 (2014) e112483. <https://doi.org/10.1371/journal.pone.0112483>.
- 920 [172] J.M. Fernández-Alvira, V. Fuster, B. Dorado, N. Soberón, I. Flores, M. Gallardo, S. Pocock,
921 M.A. Blasco, V. Andrés, Short Telomere Load, Telomere Length, and Subclinical
922 Atherosclerosis: The PESA Study, *J Am Coll Cardiol*. 67 (2016) 2467–2476.
923 <https://doi.org/10.1016/j.jacc.2016.03.530>.

- 924 [173] Y. Tamura, K. Takubo, J. Aida, A. Araki, H. Ito, Telomere attrition and diabetes mellitus,
925 *Geriatr Gerontol Int.* 16 Suppl 1 (2016) 66–74. <https://doi.org/10.1111/ggi.12738>.
- 926 [174] S. Verhulst, C. Dalgård, C. Labat, J.D. Kark, M. Kimura, K. Christensen, S. Toupance, A.
927 Aviv, K.O. Kyvik, A. Benetos, A short leucocyte telomere length is associated with
928 development of insulin resistance, *Diabetologia.* 59 (2016) 1258–1265.
929 <https://doi.org/10.1007/s00125-016-3915-6>.
- 930 [175] S. Toupance, C. Labat, M. Temmar, P. Rossignol, M. Kimura, A. Aviv, A. Benetos, Short
931 Telomeres, but Not Telomere Attrition Rates, Are Associated With Carotid Atherosclerosis,
932 Hypertension. 70 (2017) 420–425. <https://doi.org/10.1161/HYPERTENSIONAHA.117.09354>.
- 933 [176] W.M. Schultz, H.M. Kelli, J.C. Lisko, T. Varghese, J. Shen, P. Sandesara, A.A. Quyyumi,
934 H.A. Taylor, M. Gulati, J.G. Harold, J.H. Mieres, K.C. Ferdinand, G.A. Mensah, L.S. Sperling,
935 Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions,
936 *Circulation.* 137 (2018) 2166–2178.
937 <https://doi.org/10.1161/CIRCULATIONAHA.117.029652>.
- 938 [177] W. Herrmann, M. Herrmann, The Importance of Telomere Shortening for Atherosclerosis and
939 Mortality, *J Cardiovasc Dev Dis.* 7 (2020). <https://doi.org/10.3390/jcdd7030029>.
- 940 [178] Y.E. Yegorov, A.V. Poznyak, N.G. Nikiforov, A.V. Starodubova, A.N. Orekhov, Role of
941 Telomeres Shortening in Atherogenesis: An Overview, *Cells.* 10 (2021).
942 <https://doi.org/10.3390/cells10020395>.
- 943 [179] L. Peyrin-Biroulet, R. Christopher, D. Behan, C. Lassen, Modulation of sphingosine-1-
944 phosphate in inflammatory bowel disease, *Autoimmun Rev.* 16 (2017) 495–503.
945 <https://doi.org/10.1016/j.autrev.2017.03.007>.
- 946 [180] T. Sairenji, K.L. Collins, D.V. Evans, An Update on Inflammatory Bowel Disease, *Prim Care.*
947 44 (2017) 673–692. <https://doi.org/10.1016/j.pop.2017.07.010>.
- 948 [181] S. Alatab, S.G. Sepanlou, K. Ikuta, H. Vahedi, C. Bisignano, S. Safiri, A. Sadeghi, M.R.
949 Nixon, A. Abdoli, H. Abolhassani, V. Alipour, M.A.H. Almadi, A. Almasi-Hashiani, A.
950 Anushiravani, J. Arabloo, S. Atique, A. Awasthi, A. Badawi, A.A.A. Baig, N. Bhala, A.
951 Bijani, A. Biondi, A.M. Borzi, K.E. Burke, F. Carvalho, A. Daryani, M. Dubey, A. Eftekhari,
952 E. Fernandes, J.C. Fernandes, F. Fischer, A. Haj-Mirzaian, A. Haj-Mirzaian, A. Hasanzadeh,
953 M. Hashemian, S.I. Hay, C.L. Hoang, M. Househ, O.S. Ilesanmi, N.J. Balalami, S.L. James,
954 A.P. Kengne, M.M. Malekzadeh, S. Merat, T.J. Meretoja, T. Mestrovic, E.M. Mirrakhimov, H.
955 Mirzaei, K.A. Mohammad, A.H. Mokdad, L. Monasta, I. Negoi, T.H. Nguyen, C.T. Nguyen,
956 A. Pourshams, H. Poustchi, M. Rabiee, N. Rabiee, K. Ramezanzadeh, D.L. Rawaf, S. Rawaf,
957 N. Rezaei, S.R. Robinson, L. Ronfani, S. Saxena, M. Sepehrimanesh, M.A. Shaikh, Z. Sharafi,
958 M. Sharif, S. Siabani, A.R. Sima, J.A. Singh, A. Soheili, R. Sotoudehmanesh, H.A.R. Suleria,
959 B.E. Tesfay, B. Tran, D. Tsoi, M. Vacante, A.B. Wondmieneh, A. Zarghi, Z.-J. Zhang, M.
960 Dirac, R. Malekzadeh, M. Naghavi, The global, regional, and national burden of inflammatory
961 bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global
962 Burden of Disease Study 2017, *The Lancet Gastroenterology & Hepatology.* 5 (2020) 17–30.
963 [https://doi.org/10.1016/S2468-1253\(19\)30333-4](https://doi.org/10.1016/S2468-1253(19)30333-4).
- 964 [182] R. Chen, L.A. Lai, T.A. Brentnall, S. Pan, Biomarkers for colitis-associated colorectal cancer,
965 *World J Gastroenterol.* 22 (2016) 7882–7891. <https://doi.org/10.3748/wjg.v22.i35.7882>.
- 966 [183] L.A. Lai, R.A. Risques, M.P. Bronner, P.S. Rabinovitch, D. Crispin, R. Chen, T.A. Brentnall,
967 Pan-colonic field defects are detected by CGH in the colons of UC patients with

- 968 dysplasia/cancer, *Cancer Lett.* 320 (2012) 180–188.
969 <https://doi.org/10.1016/j.canlet.2012.02.031>.
- 970 [184] J.N. O’Sullivan, M.P. Bronner, T.A. Brentnall, J.C. Finley, W.-T. Shen, S. Emerson, M.J.
971 Emond, K.A. Gollahon, A.H. Moskovitz, D.A. Crispin, J.D. Potter, P.S. Rabinovitch,
972 Chromosomal instability in ulcerative colitis is related to telomere shortening, *Nat Genet.* 32
973 (2002) 280–284. <https://doi.org/10.1038/ng989>.
- 974 [185] T. Tahara, T. Shibata, M. Okubo, T. Kawamura, K. Sumi, T. Ishizuka, M. Nakamura, M.
975 Nagasaka, Y. Nakagawa, N. Ohmiya, T. Arisawa, I. Hirata, Telomere length in non-neoplastic
976 colonic mucosa in ulcerative colitis (UC) and its relationship to the severe clinical phenotypes,
977 *Clin Exp Med.* 15 (2015) 327–332. <https://doi.org/10.1007/s10238-014-0295-4>.
- 978 [186] Y. Kinouchi, N. Hiwatashi, M. Chida, F. Nagashima, S. Takagi, H. Maekawa, T. Toyota,
979 Telomere shortening in the colonic mucosa of patients with ulcerative colitis, *J Gastroenterol.*
980 33 (1998) 343–348. <https://doi.org/10.1007/s005350050094>.
- 981 [187] M. Friis-Ottessen, L. Bendix, S. Kølvråa, S. Norheim-Andersen, P.M. De Angelis, O.P.F.
982 Clausen, Telomere shortening correlates to dysplasia but not to DNA aneuploidy in
983 longstanding ulcerative colitis, *BMC Gastroenterol.* 14 (2014) 8. [https://doi.org/10.1186/1471-](https://doi.org/10.1186/1471-230X-14-8)
984 [230X-14-8](https://doi.org/10.1186/1471-230X-14-8).
- 985 [188] M. Crous-Bou, T.T. Fung, J. Prescott, B. Julin, M. Du, Q. Sun, K.M. Rexrode, F.B. Hu, I. De
986 Vivo, Mediterranean diet and telomere length in Nurses’ Health Study: population based
987 cohort study., *BMJ.* 349 (2014) g6674. <https://doi.org/10.1136/bmj.g6674>.
- 988 [189] S. Flynn, S. Eisenstein, Inflammatory Bowel Disease Presentation and Diagnosis, *Surg Clin*
989 *North Am.* 99 (2019) 1051–1062. <https://doi.org/10.1016/j.suc.2019.08.001>.
- 990 [190] F. Zink, S.N. Stacey, G.L. Norddahl, M.L. Frigge, O.T. Magnusson, I. Jonsdottir, T.E.
991 Thorgeirsson, A. Sigurdsson, S.A. Gudjonsson, J. Gudmundsson, J.G. Jonasson, L.
992 Tryggvadottir, T. Jonsson, A. Helgason, A. Gylfason, P. Sulem, T. Rafnar, U. Thorsteinsdottir,
993 D.F. Gudbjartsson, G. Masson, A. Kong, K. Stefansson, Clonal hematopoiesis, with and
994 without candidate driver mutations, is common in the elderly, *Blood.* 130 (2017) 742–752.
995 <https://doi.org/10.1182/blood-2017-02-769869>.
- 996 [191] K.E. Schratz, L. Haley, S.K. Danoff, A.L. Blackford, A.E. DeZern, C.D. Gocke, A.S. Duffield,
997 M. Armanios, Cancer spectrum and outcomes in the Mendelian short telomere syndromes,
998 *Blood.* 135 (2020) 1946–1956. <https://doi.org/10.1182/blood.2019003264>.
- 999 [192] D.P. Steensma, Clinical Implications of Clonal Hematopoiesis, *Mayo Clin Proc.* 93 (2018)
1000 1122–1130. <https://doi.org/10.1016/j.mayocp.2018.04.002>.
- 1001 [193] Y. Kang, H. Zhang, Y. Zhao, Y. Wang, W. Wang, Y. He, W. Zhang, W. Zhang, X. Zhu, Y.
1002 Zhou, L. Zhang, Z. Ju, L. Shi, Telomere Dysfunction Disturbs Macrophage Mitochondrial
1003 Metabolism and the NLRP3 Inflammasome through the PGC-1 α /TNFAIP3 Axis, *Cell Rep.* 22
1004 (2018) 3493–3506. <https://doi.org/10.1016/j.celrep.2018.02.071>.
- 1005 [194] B.K. Davis, C. Philipson, R. Hontecillas, K. Eden, J. Bassaganya-Riera, I.C. Allen, Emerging
1006 significance of NLRs in inflammatory bowel disease, *Inflamm Bowel Dis.* 20 (2014) 2412–
1007 2432. <https://doi.org/10.1097/MIB.000000000000151>.
- 1008 [195] A.-C. Villani, M. Lemire, G. Fortin, E. Louis, M.S. Silverberg, C. Collette, N. Baba, C.
1009 Libioulle, J. Belaiche, A. Bitton, D. Gaudet, A. Cohen, D. Langelier, P.R. Fortin, J.E. Wither,
1010 M. Sarfati, P. Rutgeerts, J.D. Rioux, S. Vermeire, T.J. Hudson, D. Franchimont, Common

- 1011 variants in the NLRP3 region contribute to Crohn's disease susceptibility, *Nat Genet.* 41
1012 (2009) 71–76. <https://doi.org/10.1038/ng.285>.
- 1013 [196] Y. Zhen, H. Zhang, NLRP3 Inflammasome and Inflammatory Bowel Disease, *Front Immunol.*
1014 10 (2019) 276. <https://doi.org/10.3389/fimmu.2019.00276>.
- 1015 [197] D. Chakravarti, B. Hu, X. Mao, A. Rashid, J. Li, J. Li, W.-T. Liao, E.M. Whitley, P. Dey, P.
1016 Hou, K.A. LaBella, A. Chang, G. Wang, D.J. Spring, P. Deng, D. Zhao, X. Liang, Z. Lan, Y.
1017 Lin, S. Sarkar, C. Terranova, Y.L. Deribe, S.E. Blutt, P. Okhuysen, J. Zhang, E. Vilar, O.H.
1018 Nielsen, A. Dupont, M. Younes, K.R. Patel, N.F. Shroyer, K. Rai, M.K. Estes, Y.A. Wang,
1019 A.A. Bertuch, R.A. DePinho, Telomere dysfunction activates YAP1 to drive tissue
1020 inflammation, *Nat Commun.* 11 (2020) 4766. <https://doi.org/10.1038/s41467-020-18420-w>.
- 1021 [198] A.W. Armstrong, C. Read, Pathophysiology, Clinical Presentation, and Treatment of Psoriasis:
1022 A Review, *JAMA.* 323 (2020) 1945–1960. <https://doi.org/10.1001/jama.2020.4006>.
- 1023 [199] G. Caiazzo, G. Fabbrocini, R. Di Caprio, A. Raimondo, E. Scala, N. Balato, A. Balato,
1024 Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows, *Front Immunol.* 9
1025 (2018) 1668. <https://doi.org/10.3389/fimmu.2018.01668>.
- 1026 [200] M. Kunz, J.C. Simon, A. Saalbach, Psoriasis: Obesity and Fatty Acids, *Front Immunol.* 10
1027 (2019) 1807. <https://doi.org/10.3389/fimmu.2019.01807>.
- 1028 [201] M. Dougados, D. Baeten, Spondyloarthritis, *Lancet.* 377 (2011) 2127–2137.
1029 [https://doi.org/10.1016/S0140-6736\(11\)60071-8](https://doi.org/10.1016/S0140-6736(11)60071-8).
- 1030 [202] N. Garg, F. van den Bosch, A. Deodhar, The concept of spondyloarthritis: where are we now?,
1031 *Best Pract Res Clin Rheumatol.* 28 (2014) 663–672.
1032 <https://doi.org/10.1016/j.berh.2014.10.007>.
- 1033 [203] A. Fiorelli, F. Ferraro, F. Nagar, P. Fusco, S. Mazzone, G. Costa, D. Di Natale, N. Serra, M.
1034 Santini, A New Modified Evans Blue Dye Test as Screening Test for Aspiration in
1035 Tracheostomized Patients, *J Cardiothorac Vasc Anesth.* 31 (2017) 441–445.
1036 <https://doi.org/10.1053/j.jvca.2016.07.031>.
- 1037 [204] A. Watad, C. Bridgewood, T. Russell, H. Marzo-Ortega, R. Cuthbert, D. McGonagle, The
1038 Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science,
1039 *Front Immunol.* 9 (2018) 2668. <https://doi.org/10.3389/fimmu.2018.02668>.
- 1040 [205] K.J. Wenker, J.M. Quint, Ankylosing Spondylitis, in: *StatPearls*, StatPearls Publishing,
1041 Treasure Island (FL), 2020. <http://www.ncbi.nlm.nih.gov/books/NBK470173/> (accessed
1042 January 30, 2021).
- 1043 [206] T.V. Macfarlane, H.M. Abbood, E. Pathan, K. Gordon, J. Hinz, G.J. Macfarlane, Relationship
1044 between diet and ankylosing spondylitis: A systematic review, *Eur J Rheumatol.* 5 (2018) 45–
1045 52. <https://doi.org/10.5152/eurjrheum.2017.16103>.
- 1046 [207] M. Tamayo, A. Mosquera, J.I. Rego, J.L. Fernández-Sueiro, F.J. Blanco, J.L. Fernández,
1047 Differing patterns of peripheral blood leukocyte telomere length in rheumatologic diseases,
1048 *Mutat Res.* 683 (2010) 68–73. <https://doi.org/10.1016/j.mrfmmm.2009.10.010>.
- 1049 [208] J. Sieper, D. Poddubnyy, Axial spondyloarthritis, *Lancet.* 390 (2017) 73–84.
1050 [https://doi.org/10.1016/S0140-6736\(16\)31591-4](https://doi.org/10.1016/S0140-6736(16)31591-4).
- 1051 [209] J. Fessler, A. Raicht, R. Husic, A. Ficjan, C. Duftner, W. Schwinger, C. Dejaco, M. Schirmer,
1052 Premature senescence of T-cell subsets in axial spondyloarthritis, *Ann Rheum Dis.* 75 (2016)
1053 748–754. <https://doi.org/10.1136/annrheumdis-2014-206119>.

- 1054 [210] J.A. Sparks, Rheumatoid Arthritis, *Ann Intern Med.* 170 (2019) ITC1–ITC16.
1055 <https://doi.org/10.7326/AITC201901010>.
- 1056 [211] K. Koetz, E. Bryl, K. Spickschen, W.M. O’Fallon, J.J. Goronzy, C.M. Weyand, T cell
1057 homeostasis in patients with rheumatoid arthritis, *Proc Natl Acad Sci U S A.* 97 (2000) 9203–
1058 9208. <https://doi.org/10.1073/pnas.97.16.9203>.
- 1059 [212] Y.H. Lee, S.-C. Bae, Association between shortened telomere length and rheumatoid arthritis :
1060 A meta-analysis, *Z Rheumatol.* 77 (2018) 160–167. [https://doi.org/10.1007/s00393-016-0209-](https://doi.org/10.1007/s00393-016-0209-9)
1061 9.
- 1062 [213] Z. Zeng, W. Zhang, Y. Qian, H. Huang, D.J.H. Wu, Z. He, D. Ye, Y. Mao, C. Wen,
1063 Association of telomere length with risk of rheumatoid arthritis: a meta-analysis and
1064 Mendelian randomization, *Rheumatology (Oxford).* 59 (2020) 940–947.
1065 <https://doi.org/10.1093/rheumatology/kez524>.
- 1066 [214] K. Yudoh, H. Matsuno, T. Nezuka, T. Kimura, Different mechanisms of synovial hyperplasia
1067 in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in
1068 synovial proliferation, *Arthritis Rheum.* 42 (1999) 669–677. [https://doi.org/10.1002/1529-](https://doi.org/10.1002/1529-0131(199904)42:4<669::AID-ANR9>3.0.CO;2-V)
1069 0131(199904)42:4<669::AID-ANR9>3.0.CO;2-V.
- 1070 [215] G. Wildner, M. Diedrichs-Möhrling, Resolution of uveitis, *Semin Immunopathol.* 41 (2019)
1071 727–736. <https://doi.org/10.1007/s00281-019-00758-z>.
- 1072 [216] Emmett T Cunningham, Nikolas JS London & Sivakumar R Rathinam, Uveitis: a global view,
1073 2010.
- 1074 [217] A. Aviv, S.C. Hunt, J. Lin, X. Cao, M. Kimura, E. Blackburn, Impartial comparative analysis
1075 of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR,
1076 *Nucleic Acids Res.* 39 (2011) e134. <https://doi.org/10.1093/nar/gkr634>.
- 1077 [218] D. Nettle, L. Seeker, D. Nussey, H. Froy, M. Bateson, Consequences of measurement error in
1078 qPCR telomere data: A simulation study, *PLoS One.* 14 (2019) e0216118.
1079 <https://doi.org/10.1371/journal.pone.0216118>.
- 1080 [219] M. Bateson, D. Nettle, Why are there associations between telomere length and behaviour?,
1081 *Philos Trans R Soc Lond B Biol Sci.* 373 (2018). <https://doi.org/10.1098/rstb.2016.0438>.
- 1082 [220] M. Bateson, D.T.A. Eisenberg, D. Nettle, Controlling for baseline telomere length biases
1083 estimates of the rate of telomere attrition, *R Soc Open Sci.* 6 (2019) 190937.
1084 <https://doi.org/10.1098/rsos.190937>.
- 1085 [221] R.M. Cawthon, Telomere measurement by quantitative PCR, *Nucleic Acids Res.* 30 (2002)
1086 e47. <https://doi.org/10.1093/nar/30.10.e47>.
- 1087 [222] A.J. Montpetit, A.A. Alhareeri, M. Montpetit, A.R. Starkweather, L.W. Elmore, K. Filler, L.
1088 Mohanraj, C.W. Burton, V.S. Menzies, D.E. Lyon, C.K. Jackson-Cook, Telomere length: a
1089 review of methods for measurement, *Nurs Res.* 63 (2014) 289–299.
1090 <https://doi.org/10.1097/NNR.0000000000000037>.
- 1091 [223] G. Aubert, M. Hills, P.M. Lansdorp, Telomere length measurement-caveats and a critical
1092 assessment of the available technologies and tools, *Mutat Res.* 730 (2012) 59–67.
1093 <https://doi.org/10.1016/j.mrfmmm.2011.04.003>.
- 1094 [224] H.B. Fleisig, J.M.Y. Wong, Telomerase as a clinical target: current strategies and potential
1095 applications, *Exp Gerontol.* 42 (2007) 102–112. <https://doi.org/10.1016/j.exger.2006.05.011>.

- 1096 [225] P. Martínez, M.A. Blasco, Telomere-driven diseases and telomere-targeting therapies, *J Cell*
1097 *Biol.* 216 (2017) 875–887. <https://doi.org/10.1083/jcb.201610111>.
- 1098 [226] S. Cacchione, A. Biroccio, A. Rizzo, Emerging roles of telomeric chromatin alterations in
1099 cancer, *J Exp Clin Cancer Res.* 38 (2019) 21. <https://doi.org/10.1186/s13046-019-1030-5>.
- 1100 [227] J.-L. Mergny, L. Guittat, É. Ségal-Bendirdjian, [Are telomeres and telomerase still relevant
1101 targets in oncology?], *Bull Cancer.* 108 (2021) 30–38.
1102 <https://doi.org/10.1016/j.bulcan.2020.10.007>.
- 1103 [228] P. Viswanath, G. Batsios, J. Mukherjee, A.M. Gillespie, P.E.Z. Larson, H.A. Luchman, J.J.
1104 Phillips, J.F. Costello, R.O. Pieper, S.M. Ronen, Non-invasive assessment of telomere
1105 maintenance mechanisms in brain tumors, *Nat Commun.* 12 (2021) 92.
1106 <https://doi.org/10.1038/s41467-020-20312-y>.
- 1107 [229] M. Ivancich, Z. Schrank, L. Wojdyla, B. Leviskas, A. Kuckovic, A. Sanjali, N. Puri, Treating
1108 Cancer by Targeting Telomeres and Telomerase, *Antioxidants (Basel).* 6 (2017) E15.
1109 <https://doi.org/10.3390/antiox6010015>.
- 1110 [230] B. Usselman, M. Newbold, A.G. Morris, C.U. Nwokolo, Deficiency of colonic telomerase in
1111 ulcerative colitis, *Am J Gastroenterol.* 96 (2001) 1106–1112. <https://doi.org/10.1111/j.1572-0241.2001.03752.x>.
- 1112 [231] B. Meresse, S. Dubucquoi, B. Tourvieille, P. Desreumaux, J.F. Colombel, J.P. Dessaint,
1113 CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal
1114 mucosa in Crohn disease, *Hum Immunol.* 62 (2001) 694–700. [https://doi.org/10.1016/s0198-8859\(01\)00258-0](https://doi.org/10.1016/s0198-8859(01)00258-0).

1117

1118

1119








1120

1121






1122 **9 Captions figure.**

1123 **Fig.1: (A) Telomere maintenance components, (B) Telomere length reported in IMID's.** (A)
1124 Telomeres are composed of hundreds or thousands of repeated DNA sequences of TTAGGG in one
1125 strand and CCCTAA in the other. The shelterin complex consist of six proteins (TRF1, TRF2, RAP1,
1126 POT1, TPP1 and TIN2) and provides protection of the telomere end, facilitates telomeric DNA
1127 replication and recruitment of telomerase to the telomere. The telomerase complex consists of the
1128 enzyme telomerase-transcriptase (TERT), the RNA component (TERC) and the protein complex
1129 dyskerin (dyskerin, NOP10, NHP2 and GAR1). This complex allows telomere elongation via TERT
1130 by adding TTAGGG repeats and has extratelomeric functions.

1131 **Table 1: Overview of recent studies investigating the relationship between telomere dynamics and IMIDs.** AD = atopic dermatitis;
 1132 aSpA : axial spondyloarthritis; CD = Crohn's disease; IBDs = inflammatory bowel diseases; IMIDs = Immune-mediated inflammatory
 1133 diseases; PBMCs = peripheral blood mononuclear cells; UC = ulcerative colitis. Consistence between methodology and conclusion are
 1134 highlight in blue.

IMID	Study reference	Populations / design		Results	Authors' conclusion
		Cases	Controls		
Inflammatory bowel diseases					
IBD	Tutra et al. [57]	11 patients (5 UC, 4 CD, 2 IBD-U) 8 parent-child pairs from 3 families <i>Johns Hopkins IBD Family Study</i>		 Median age at diagnosis of children 16.5 younger	Telomere shortening appears unlikely to be involved in mechanisms of possible genetic anticipation in IBD.
IBD	Da-Silva et al. [61]	18 UC / 13 CD patients 49 / 44 years <i>Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry UK</i>	13 non-IBD controls 56 years	 TRF2 / RAP1 / TRF1	The downregulation of TRF2 and RAP1 mRNA expression in CD25+ T-lymphocytes in IBD suggests that these telomere binding proteins play a role in telomere regulation and may contribute to the telomeric fusions and chromosomal abnormalities observed in UC. These findings may also indicate a systemic process of telomere uncapping which could represent a biomarker for IBD associated cancer risk.
UC	Usselmann et al. [230]	25 UC 11 colorectal cancer 9 adenomatous polyps <i>Department of Gastroenterology, University Hospitals Coventry and Warwickshire NHS Trust UK</i>	21 normal colons	 UC cancer	Colonic mucosal expression of telomerase is reduced in UC. Levels are low even in microscopically normal mucosa, suggesting that telomerase deficiency may contribute to the pathogenesis of the disease.
UC	Tahara et al. [185]	86 UC / 37.3 years ± 11.4 median clinical duration = 6.9 years ± 5.8 <i>Department of Gastroenterology, Fujita Health University School of Medicine Japan</i>	normal appearing proximal colon of same individuals	 + severe clinical phenotypes	Telomere shortening is associated with more severe clinical phenotypes of UC, reflecting severe inflammatory state in the colonic mucosa.
UC	Risques et al. [58]	85 UC (biopsies) / 14-79 years 102 UC (leukocyte DNA) / 31-80 years 43 UC (paraffin-embedded colon) / 31-78 years <i>Department of Pathology, University of Washington, Seattle USA</i>	79 normal colon controls / 2-79 years 45 controls / 3-79 years 53 controls / 31-79 years	 colonocytes / leukocytes	Colonocytes of UC patients show premature shortening of telomeres, which might explain the increased and earlier risk of cancer in this disease. Shorter leukocyte telomeres and increased γH2AX in colonocytes might reflect oxidative damage secondary to inflammation.
UC	Getliffe et al. [60]	19 UC / 45 years 17 CD / 48 years <i>Department of Biological Sciences, University of Warwick, Coventry UK</i>	18 controls / 56 years	 + azathioprine / + smoking	Telomere shortening is not accelerated and therefore cannot be the cause of the chromosome instability observed in UC peripheral blood lymphocytes. Azathioprine and cigarette smoking modify telomerase expression in these cells.
UC	Salk et al. [62]	14 Progressors UC patients <i>Cleveland Clinic USA</i>	19 Non-Progressors UC patients	 non-dysplastic biopsies & early onset + clonal expansion in non-dysplastic biopsies	Early-onset progressors develop cancer in a field of clonally expanded epithelium with shorter telomeres. The detection of these clones in a few random nondysplastic colon biopsies is a promising cancer biomarker in early-onset UC. Curiously, patients with late-onset UC seem to develop cancer without the involvement of such fields.

UC-associated colorectal cancer	Risques et al. [59]	9 UC patients with high-grade dysplasia (biopsies located less than 10 cm from HGD) <i>Department of Pathology, University of Washington, Seattle USA</i>	4 UC patients without dysplasia		Dysplasia arises in a preneoplastic field of chronic inflammation, which leads to telomere shortening, DNA damage, and senescence. Senescence acts as a tumor suppressor mechanism that is abrogated during the transition from LGD to HGD in UC.
CD	Meresse et al. [231]	Surgical samples from 27 patients undergoing ileo-colonic resection for CD 19-52 years <i>Service d'Immunologie, EA 2686, Lille France</i>	Non inflammatory mucosa collected in the healthy mucosa of resected ileum from 10 patients with colonic cancers / 53-82 years		In the uninvolved ileal mucosa, IEL from CD patients had shorter telomeric lengths than IEL from control patients, suggesting that they have been chronically stimulated. Such perturbation of the IEL population within the ileal mucosa could contribute to the inflammation in CD.
Rheumatoid arthritis					
RA	Colmegna et al. [68]	63 patients with diagnosis of seropositive RA according to the American College of Rheumatology 1987 revised criteria 55 years ± 14 <i>Rheumatology Clinic Emory University School of Medicine, Atlanta</i>	48 age-, sex- and ethnically- frequency matched healthy subjects without history of chronic inflammatory diseases or immunosuppressive/chem otherapeutic therapy 52 years ± 14		Decrease of circulating bone marrow-derived progenitor cells. Concentrations stagnated at levels typical of those in old control subjects. Hematopoietic precursor cells displayed growth factor nonresponsiveness and sluggish cell cycle progression; marked telomere shortening indicated proliferative stress-induced senescence. Defective HPC function independent of disease activity markers suggests bone marrow failure as a potential pathogenic factor in RA.
RA	Fujii et al. [70]	69 patients / 50.5 years ± 14 <i>Department of Medicine, Lowance Center for Human Immunology and Rheumatology, Emory University School of Medicine Atlanta, USA</i>	60 healthy control / 47.6 years ± 12		Telomerase insufficiency in RA results in excessive T cell loss, undermining homeostatic control of the naive T cell compartment and setting the stage for lymphopenia-induced T cell repertoire remodeling. Restoring defective telomerase activity emerges as a therapeutic target in resetting immune abnormalities in RA.
RA	Steer et al. [67]	176 RA patients / 63.8 years <i>Guy's, St Thomas' and Lewisham hospitals in London, UK</i>	1151 controls / 8.2 years		Reduced terminal restriction fragment length in a large group of patients with RA, apparently independent of disease duration and markers of disease severity, but is influenced by HLA-DRB1 genotype.
RA	Koetz et al. [211]	51 rheumatoid arthritis / 13-80 years	47 healthy controls / 18-77 years		Increased self-replication of CD4+CD45ROnull T cells is thought to lead to premature erosion of telomeres. This reduced terminal restriction fragment length has functional consequences that may explain the increased susceptibility of RA patients to contract infection.
Spondyloarthritis					
	Tamayo et al. [207]	86 rheumatoid arthritis / 31-82 years 56 psoriatic arthritis / 26-79 years 59 ankylosing spondylitis / 21-75 years <i>Hospital Universitario de A Coruña Spain</i>	130 healthy controls / 3-94 years		The presence of chronic inflammatory component in rheumatologic diseases could be associated to higher telomere size in PBL, unlike in healthy controls.
	Tamayo et al. [66]	42 psoriatic arthritis patients / 55.02 years ± 14.33 44 ankylosing spondylitis patients / 49.07 years ± 14.58 <i>Hospital Universitario de A Coruña Spain</i>	53 psoriasis at baseline / 53.75 years ± 16.37		The presence of chronic inflammatory component in PsA could be associated to a higher telomere size in PBL, unlike in cutaneous Ps. The rate of telomere loss in PBL is higher in PsA patients than in AS patients, revealing a difference in telomere physiology from PBL between both spondyloarthritis. The qPCR methodology is sensitive enough to evidence a significant telomere length shortening in specific subjects in a few years, so it could be useful for follow-up in patients.

	Fessler et al. [209]	51 axial spondyloarthritis (aSpA) / 40.7 years ± 12.9 51 rheumatoid arthritis / 52.3 years ± 18.2	50 healthy controls / 45.6 years ± 13.3		Increased homeostatic proliferation of T-cells leads to premature shortening of telomeres that is not restored by telomerase enzyme.
Chronic inflammatory skin diseases					
Psoriasis	Liu et al. [63]	30 psoriatic patients / 34.03 years ± 7.38 <i>Department of Dermatology Affiliated Hospital of Dalian Medical University China</i>	13 healthy donors / 29.61 years ± 5.14		Positive correlation between telomerase activity in PBMC and disease severity of psoriasis, but not duration. Telomerase activity in PBMC may serve as an objective indicator of psoriasis severity, and inhibiting telomerase activity may become a new target for psoriasis therapy.
Atopic dermatitis	Wu et al. [65]	15 patients with moderate to severe disease activity / 23-47 years <i>Department of Dermatology Marselisborg Hospital, University of Aarhus Denmark</i>	13 healthy donors / 24-40 years		Increased telomerase activity detected in freshly obtained PBMC from patients with AD, indicating the lymphocytes have already been activated <i>in vivo</i> or that a subpopulation of 'immature' lymphocytes may be present. No difference between normal and AD patients in the DNA synthesis of their PBMC. Relative reduced telomerase activity of PBMC to multiple stimulators in patients with AD seemed to be associated with their excessive stimulation <i>in vivo</i> and their decreased functional capacity <i>in vitro</i> .
Atopic dermatitis	Wu et al. [64]	32 AD patients with moderate to severe disease activity / 17-59 years 16 psoriatic patients / 20-84 years <i>Department of Dermatology Marselisborg Hospital, University of Aarhus Denmark</i>	30 healthy blood donors / 20-84 years	 PBMC / CD4+ > CD8+	The increased telomerase activity and shortened telomere length indicates that T lymphocytes in atopic dermatitis and psoriasis are chronically stimulated and have an increased cellular turnover <i>in vivo</i> .
Birdshot Uveitis					
	Vazirpanah et al. [73]	91 unrelated BU cases of European descent / 60.5 years (9.07) <i>Department of Ophthalmology at the University Medical Center Utrecht The Netherlands</i>	150 unrelated healthy controls / 52.9 years (7.16)		BU is accompanied by significantly longer LTL.

